dermatomyositis: Dermatomyositis (DM) is a type of idiopathic inflammatory myopathy characterized by evocative skin lesions and symmetrical proximal muscle weakness.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519870 |
1. Apply sex-specific ruleNone |
519870 |
2. Check conditionsNone |
519870 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
184 |
4. Check minimum number of eventsNone |
184 |
5. Include endpointsNone |
184 |
6. Filter based on genotype QC (FinnGen only) |
177 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M33
- Name in latin
- Alia dermatomyositis
Similar endpoints
↥List of similar endpoints to
Other dermatomyositis
based on the number of shared cases.
Similar with more cases:
- Dermatopolymyositis (FG)
- Dermatopolymyositis
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Autoimmune diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 994 | 672 | 312 |
| Only index persons | 759 | 525 | 234 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 54.13 | 53.64 | 54.89 |
| Only index persons | 51.33 | 51.38 | 51.23 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 177 | 125 | 52 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.02 |
| Median age at first event (years) | 53.98 | 52.75 | 56.94 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 184
- Matched controls
- 1840
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M33.1
ICD-10 Finland
Other dermatomyositis
+∞
235.8
172
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
25.5
115.4
113
108
P01BA02
ATC
hydroxychloroquine; oral
20.2
87.3
83
72
M33.9
ICD-10 Finland
Dermatopolymyositis, unspecified
+∞
86.4
76
*
L04AX01
ATC
azathioprine; systemic
31.8
79.7
56
25
L04AX03
ATC
methotrexate; systemic
16.5
79.5
88
97
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
11.8
53.7
68
87
M33.2
ICD-10 Finland
Polymyositis
+∞
42.3
39
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
7.1
36.6
131
473
H02AB06
ATC
prednisolone; systemic
8.8
35.4
152
643
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
10.8
34.6
42
49
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
8.5
31.9
48
73
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
314.4
27.5
27
*
H02AB07
ATC
prednisone; oral
6.2
27.0
58
127
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
9.3
26.9
36
47
M05BA04
ATC
alendronic acid; oral
6.9
26.4
48
89
NXL00
NOMESCO Finland
Biopsy of muscle
274.2
24.3
24
*
L04AA06
ATC
mycophenolic acid; systemic
42.6
23.8
29
8
ZX120
NOMESCO Finland
Intravenous
6.1
20.6
41
82
L04AD01
ATC
ciclosporin; systemic
28.7
18.8
25
10
L01BA01
ATC
methotrexate; systemic
14.1
17.1
29
24
M33.0
ICD-10 Finland
Juvenile dermatomyositis
+∞
16.9
16
*
M60.9
ICD-10 Finland
Myositis, unspecified
99.3
16.9
18
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.6
16.0
86
363
L30.9
ICD-10 Finland
Dermatitis, unspecified
3.7
15.5
66
239
71600
ICD-8 Finland
Polymyositis and dermatomyositis, Dermatomyositis
+∞
14.8
14
*
M33
ICD-10 Finland
Dermatopolymyositis
+∞
14.8
14
*
D07AC01
ATC
betamethasone; topical
3.3
14.0
94
447
7103B
ICD-9 Finland
Diffuse diseases of connective tissue, Dermatomyositis[DERMATOMYOSITIS ADULTORUM]
+∞
13.7
13
*
G72.9
ICD-10 Finland
Myopathy, unspecified
24.7
13.2
18
8
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.2
13.1
117
649
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
26.6
12.7
17
7
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
17.5
12.4
19
12
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
40.5
12.4
15
*
R4110
NOMESCO Finland
Physiotherapy
3.1
12.3
81
375
UGC12
NOMESCO Finland
Flexible bronchoscopy
5.1
11.9
27
60
L04AA01
ATC
[U] ciclosporin
24.8
11.8
16
7
D07AB08
ATC
desonide; topical
3.9
11.8
40
122
J99.1*M33.9
ICD-10 Finland
Respiratory disorders in dermatopolymyositis
+∞
11.6
11
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.9
11.5
39
119
L88
ICPC
Rheumatoid/seropositive arthritis
6.3
11.3
20
35
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
46.3
11.1
13
*
M05BA07
ATC
risedronic acid; oral
8.6
10.8
23
30
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.4
10.6
46
165
D07AC13
ATC
mometasone; topical
2.9
10.5
72
335
M60.8
ICD-10 Finland
Other myositis
116.4
10.5
11
*
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
116.4
10.5
11
*
J99.1*M33.2
ICD-10 Finland
Respiratory disorders in polymyositis
+∞
10.5
10
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
34.7
10.5
13
*
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
4.6
10.4
27
67
M05BX04
ATC
denosumab; parenteral
5.0
9.6
22
49
XX9XE
NOMESCO Finland
Other ultrasound examination
23.2
9.5
13
6
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
9.5
9
*
1XC02, ,
NOMESCO Finland
+∞
9.5
9
*
XQ848
NOMESCO Finland
Dermatological photography
9.1
9.3
19
23
R4120
NOMESCO Finland
Occupational therapy
4.2
9.3
27
73
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
38.8
9.1
11
*
JN4BD
NOMESCO Finland
Extensive body CT
3.6
8.9
33
106
L93.0
ICD-10 Finland
Discoid lupus erythematosus
94.2
8.5
9
*
E0000UV, ,
ATC
2.5
8.5
97
569
QBA99
NOMESCO Finland
Other local destruction of skin of trunk
35.0
8.2
10
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.6
7.8
61
297
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
4.5
7.8
20
49
Z3226
NOMESCO Finland
Physiotherapist
2.7
7.7
52
235
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
9.5
7.7
15
17
M13.9
ICD-10 Finland
Arthritis, unspecified
3.9
7.6
24
69
HA1AA
NOMESCO Finland
X-ray mammography
3.4
7.6
29
95
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
83.3
7.5
8
*
Z2221
NOMESCO Finland
Medical doctor
2.4
7.5
69
363
R4190
NOMESCO Finland
Nutritional therapy
6.8
7.5
18
29
D07AB02
ATC
hydrocortisone butyrate; topical
2.4
7.4
70
372
XPX04
NOMESCO Finland
Angioscopy
+∞
7.3
7
*
L99
ICPC
Musculoskeletal disease other
8.5
7.3
15
19
M81.4
ICD-10 Finland
Drug-induced osteoporosis
31.4
7.2
9
*
XG410
NOMESCO Finland
Flow-volume spirometry
7.5
7.2
16
23
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
10.7
7.2
13
13
TPH04
NOMESCO Finland
Cathetrisation of vein
2.6
7.1
52
245
TQW80
NOMESCO Finland
Local dermatologic skincare
8.8
7.0
14
17
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
41.6
6.8
8
*
ZXE10
NOMESCO Finland
More than one and less than three hours
2.2
6.4
82
489
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
3.2
6.4
27
94
D02AE01
ATC
carbamide; topical
4.0
6.3
18
48
TGC00
NOMESCO Finland
Bronchial lavation
8.1
6.2
13
17
Z01.8
ICD-10 Finland
Other specified special examinations
2.4
6.2
51
252
C03CA01
ATC
furosemide; systemic
2.2
6.1
67
374
E000001, ,
ATC
2.4
6.1
48
232
TimeCodeWAS
↥TODO / Current known limitations:
- Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
- Legend / how to read the glyphs.
- Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
- Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
- Download CSV.
- No filters and sorters.
- Limited amount of endpoints (~400) having TimeCodeWAS data.
- Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
prednisolone; oral, parenteral
H02AB06 [21602734]
H02AB06 [21602734]
1.8e+00
3.0e+00
4.5e+00
1.0e+50
4.8e+00
3.9e+00
2.7e+00
cases:31.76%
controls:7.01%
cases:40.59%
controls:3.24%
cases:21.18%
controls:0.29%
cases:7.06%
controls:0.00%
cases:26.63%
controls:0.30%
cases:59.76%
controls:2.88%
cases:58.62%
controls:8.63%
54
119
116
1578
69
55
101
1642
36
5
134
1692
12
0
158
1697
45
5
124
1686
98
48
66
1619
85
134
60
1418
prednisolone
A07EA01 [21600653]
A07EA01 [21600653]
1.8e+00
3.0e+00
4.5e+00
1.0e+50
4.8e+00
3.9e+00
2.7e+00
cases:31.76%
controls:7.07%
cases:40.59%
controls:3.24%
cases:21.18%
controls:0.29%
cases:7.06%
controls:0.00%
cases:26.63%
controls:0.30%
cases:59.76%
controls:2.88%
cases:58.62%
controls:8.83%
54
120
116
1577
69
55
101
1642
36
5
134
1692
12
0
158
1697
45
5
124
1686
98
48
66
1619
85
137
60
1415
methotrexate; oral, parenteral
L04AX03 [21603929]
L04AX03 [21603929]
2.6e+00
2.4e+00
3.0e+00
—
3.6e+00
4.1e+00
3.7e+00
cases:10.59%
controls:0.88%
cases:10.59%
controls:1.06%
cases:6.47%
controls:0.35%
—
—
cases:9.47%
controls:0.30%
cases:32.93%
controls:0.84%
cases:37.24%
controls:1.42%
18
15
152
1682
18
18
152
1679
11
6
159
1691
—
16
5
153
1686
54
14
110
1653
54
22
91
1530
methotrexate
L01BA01 [21601423]
L01BA01 [21601423]
2.6e+00
2.4e+00
3.0e+00
—
3.6e+00
4.1e+00
3.7e+00
cases:10.59%
controls:0.88%
cases:10.59%
controls:1.06%
cases:6.47%
controls:0.35%
—
—
cases:9.47%
controls:0.30%
cases:32.93%
controls:0.84%
cases:37.24%
controls:1.42%
18
15
152
1682
18
18
152
1679
11
6
159
1691
—
16
5
153
1686
54
14
110
1653
54
22
91
1530
Rheumatology
66 [38004491]
66 [38004491]
2.5e+00
4.3e+00
—
1.0e+50
—
5.5e+00
4.4e+00
cases:19.41%
controls:1.89%
cases:29.41%
controls:0.59%
—
—
cases:30.00%
controls:0.00%
—
—
cases:64.63%
controls:0.72%
cases:62.07%
controls:1.93%
33
32
137
1665
50
10
120
1687
—
51
0
119
1697
—
106
12
58
1655
90
30
55
1522
calcium (different salts in combination); oral
A12AA20 [21600872]
A12AA20 [21600872]
2.0e+00
2.5e+00
2.2e+00
—
3.2e+00
3.1e+00
2.7e+00
cases:26.47%
controls:4.83%
cases:29.41%
controls:3.24%
cases:8.24%
controls:0.94%
—
—
cases:14.79%
controls:0.71%
cases:47.56%
controls:4.08%
cases:54.48%
controls:7.47%
45
82
125
1615
50
55
120
1642
14
16
156
1681
—
25
12
144
1679
78
68
86
1599
79
116
66
1436
Outpatient Visit
OP [9202]
OP [9202]
7.5e-01
1.1e+00
1.9e+00
5.7e+00
2.1e+00
2.0e+00
1.5e+00
cases:77.65%
controls:62.11%
cases:65.88%
controls:40.25%
cases:37.06%
controls:7.84%
cases:56.47%
controls:0.41%
cases:45.56%
controls:8.93%
cases:83.54%
controls:40.61%
cases:92.41%
controls:72.55%
132
1054
38
643
112
683
58
1014
63
133
107
1564
96
7
74
1690
77
151
92
1540
137
677
27
990
134
1126
11
426
hydroxychloroquine; oral
P01BA02 [21604889]
P01BA02 [21604889]
2.8e+00
3.2e+00
—
—
—
4.1e+00
3.7e+00
cases:10.00%
controls:0.65%
cases:11.18%
controls:0.53%
—
—
—
—
—
—
cases:25.00%
controls:0.54%
cases:28.97%
controls:1.03%
17
11
153
1686
19
9
151
1688
—
—
—
41
9
123
1658
42
16
103
1536
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
207NI0002X [38003841]
6.8e-01
2.9e+00
—
1.0e+50
4.4e+00
3.4e+00
2.3e+00
cases:10.59%
controls:5.66%
cases:24.71%
controls:1.71%
—
—
cases:37.06%
controls:0.00%
cases:22.49%
controls:0.35%
cases:37.80%
controls:2.04%
cases:39.31%
controls:6.06%
18
96
152
1601
42
29
128
1668
—
63
0
107
1697
38
6
131
1685
62
34
102
1633
57
94
88
1458
Pulmonary Disease
29 [38004472]
29 [38004472]
1.4e+00
1.7e+00
2.3e+00
1.0e+50
3.0e+00
2.2e+00
1.6e+00
cases:18.24%
controls:5.24%
cases:16.47%
controls:3.42%
cases:4.71%
controls:0.47%
cases:3.53%
controls:0.00%
cases:7.69%
controls:0.41%
cases:21.34%
controls:2.82%
cases:28.28%
controls:7.15%
31
89
139
1608
28
58
142
1639
8
8
162
1689
6
0
164
1697
13
7
156
1684
35
47
129
1620
41
111
104
1441
Eosinophils [#/volume] in Blood
26449-9 [3013115]
26449-9 [3013115]
-1.2e-02
1.3e+00
3.4e+00
—
3.3e+00
2.2e+00
1.8e+00
cases:6.47%
controls:6.54%
cases:13.53%
controls:4.07%
cases:17.06%
controls:0.65%
—
—
cases:11.24%
controls:0.47%
cases:22.56%
controls:3.12%
cases:40.00%
controls:9.73%
11
111
159
1586
23
69
147
1628
29
11
141
1686
—
19
8
150
1683
37
52
127
1615
58
151
87
1401
Monocytes [#/volume] in Blood
26484-6 [3001604]
26484-6 [3001604]
1.2e-01
1.4e+00
3.4e+00
—
3.2e+00
2.2e+00
1.9e+00
cases:7.06%
controls:6.31%
cases:13.53%
controls:3.83%
cases:16.47%
controls:0.65%
—
—
cases:11.24%
controls:0.53%
cases:22.56%
controls:3.06%
cases:40.00%
controls:9.15%
12
107
158
1590
23
65
147
1632
28
11
142
1686
—
19
9
150
1682
37
51
127
1616
58
142
87
1410
Basophils [#/volume] in Blood
26444-0 [3006315]
26444-0 [3006315]
2.8e-02
1.4e+00
3.4e+00
—
3.2e+00
2.2e+00
1.9e+00
cases:6.47%
controls:6.31%
cases:13.53%
controls:3.83%
cases:16.47%
controls:0.65%
—
—
cases:11.24%
controls:0.53%
cases:22.56%
controls:3.06%
cases:40.00%
controls:9.21%
11
107
159
1590
23
65
147
1632
28
11
142
1686
—
19
9
150
1682
37
51
127
1616
58
143
87
1409
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
26474-7 [3019198]
8.2e-02
1.3e+00
3.3e+00
—
3.2e+00
2.2e+00
1.8e+00
cases:7.06%
controls:6.54%
cases:13.53%
controls:4.07%
cases:16.47%
controls:0.71%
—
—
cases:11.24%
controls:0.53%
cases:22.56%
controls:3.24%
cases:40.00%
controls:9.60%
12
111
158
1586
23
69
147
1628
28
12
142
1685
—
19
9
150
1682
37
54
127
1613
58
149
87
1403
Basophils/Leukocytes in Blood
30180-4 [3022096]
30180-4 [3022096]
8.8e-03
1.3e+00
3.2e+00
—
3.1e+00
2.1e+00
1.9e+00
cases:5.88%
controls:5.83%
cases:12.94%
controls:3.71%
cases:14.71%
controls:0.71%
—
—
cases:10.65%
controls:0.53%
cases:20.73%
controls:3.06%
cases:37.93%
controls:8.57%
10
99
160
1598
22
63
148
1634
25
12
145
1685
—
18
9
151
1682
34
51
130
1616
55
133
90
1419
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
26450-7 [3006504]
-1.2e-02
1.3e+00
3.2e+00
—
3.1e+00
2.1e+00
1.9e+00
cases:5.88%
controls:5.95%
cases:12.35%
controls:3.71%
cases:14.71%
controls:0.71%
—
—
cases:10.65%
controls:0.53%
cases:20.73%
controls:3.06%
cases:38.62%
controls:8.44%
10
101
160
1596
21
63
149
1634
25
12
145
1685
—
18
9
151
1682
34
51
130
1616
56
131
89
1421
Monocytes/Leukocytes in Blood
26485-3 [3019069]
26485-3 [3019069]
1.8e-01
1.3e+00
3.2e+00
—
3.1e+00
2.1e+00
1.9e+00
cases:7.06%
controls:5.95%
cases:12.35%
controls:3.71%
cases:14.71%
controls:0.71%
—
—
cases:10.65%
controls:0.53%
cases:20.73%
controls:3.06%
cases:38.62%
controls:8.51%
12
101
158
1596
21
63
149
1634
25
12
145
1685
—
18
9
151
1682
34
51
130
1616
56
132
89
1420
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
26478-8 [3002030]
1.3e-01
1.3e+00
3.2e+00
—
3.1e+00
2.1e+00
1.8e+00
cases:7.06%
controls:6.25%
cases:12.94%
controls:3.71%
cases:14.71%
controls:0.71%
—
—
cases:10.65%
controls:0.53%
cases:20.73%
controls:3.18%
cases:38.62%
controls:9.02%
12
106
158
1591
22
63
148
1634
25
12
145
1685
—
18
9
151
1682
34
53
130
1614
56
140
89
1412
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
26511-6 [3018010]
2.6e-01
1.2e+00
3.3e+00
—
2.8e+00
2.0e+00
1.9e+00
cases:7.65%
controls:6.01%
cases:12.35%
controls:3.89%
cases:14.71%
controls:0.65%
—
—
cases:8.28%
controls:0.53%
cases:20.12%
controls:3.30%
cases:38.62%
controls:8.96%
13
102
157
1595
21
66
149
1631
25
11
145
1686
—
14
9
155
1682
33
55
131
1612
56
139
89
1413
Differential panel, method unspecified - Blood
69738-3 [42870588]
69738-3 [42870588]
1.2e-01
1.4e+00
2.9e+00
—
2.9e+00
2.0e+00
1.6e+00
cases:4.12%
controls:3.65%
cases:9.41%
controls:2.53%
cases:10.00%
controls:0.59%
—
—
cases:8.28%
controls:0.47%
cases:15.24%
controls:2.34%
cases:24.14%
controls:6.12%
7
62
163
1635
16
43
154
1654
17
10
153
1687
—
14
8
155
1683
25
39
139
1628
35
95
110
1457
Office Visit
OMOP4822458 [581477]
OMOP4822458 [581477]
9.1e-01
1.2e+00
2.5e+00
—
2.7e+00
2.0e+00
1.4e+00
cases:16.47%
controls:7.37%
cases:7.65%
controls:2.36%
cases:3.53%
controls:0.29%
—
—
cases:5.92%
controls:0.41%
cases:15.24%
controls:2.28%
cases:23.45%
controls:7.09%
28
125
142
1572
13
40
157
1657
6
5
164
1692
—
10
7
159
1684
25
38
139
1629
34
110
111
1442
prednisone; oral
H02AB07 [21602735]
H02AB07 [21602735]
2.3e+00
2.7e+00
—
—
—
3.2e+00
2.6e+00
cases:10.00%
controls:1.06%
cases:7.06%
controls:0.53%
—
—
—
—
—
—
cases:10.98%
controls:0.48%
cases:15.17%
controls:1.35%
17
18
153
1679
12
9
158
1688
—
—
—
18
8
146
1659
22
21
123
1531
prednisone
A07EA03 [21600655]
A07EA03 [21600655]
2.3e+00
2.7e+00
—
—
—
3.2e+00
2.6e+00
cases:10.00%
controls:1.06%
cases:7.06%
controls:0.53%
—
—
—
—
—
—
cases:10.98%
controls:0.48%
cases:15.17%
controls:1.35%
17
18
153
1679
12
9
158
1688
—
—
—
18
8
146
1659
22
21
123
1531
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
751-8 [3013650]
1.0e-01
1.2e+00
2.9e+00
—
2.7e+00
2.0e+00
1.9e+00
cases:8.24%
controls:7.48%
cases:13.53%
controls:4.66%
cases:14.71%
controls:0.94%
—
—
cases:11.83%
controls:0.89%
cases:22.56%
controls:3.78%
cases:42.07%
controls:10.12%
14
127
156
1570
23
79
147
1618
25
16
145
1681
—
20
15
149
1676
37
63
127
1604
61
157
84
1395
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
4537-7 [3013707]
3.2e-01
1.4e+00
3.1e+00
1.0e+50
3.0e+00
1.6e+00
1.3e+00
cases:12.94%
controls:9.78%
cases:20.00%
controls:5.66%
cases:17.06%
controls:0.94%
cases:3.53%
controls:0.00%
cases:10.06%
controls:0.53%
cases:21.95%
controls:5.40%
cases:42.07%
controls:16.24%
22
166
148
1531
34
96
136
1601
29
16
141
1681
6
0
164
1697
17
9
152
1682
36
90
128
1577
61
252
84
1300
Internal Medicine
11 [38004456]
11 [38004456]
7.8e-01
1.4e+00
2.3e+00
—
2.8e+00
1.9e+00
1.1e+00
cases:35.29%
controls:20.04%
cases:27.65%
controls:8.60%
cases:10.59%
controls:1.18%
—
—
cases:15.38%
controls:1.12%
cases:36.59%
controls:8.04%
cases:41.38%
controls:18.62%
60
340
110
1357
47
146
123
1551
18
20
152
1677
—
26
19
143
1672
60
134
104
1533
60
289
85
1263
Inpatient Hospital
21 [8717]
21 [8717]
7.7e-01
1.4e+00
2.4e+00
—
2.6e+00
1.8e+00
9.1e-01
cases:46.47%
controls:28.76%
cases:29.41%
controls:9.31%
cases:11.18%
controls:1.12%
—
—
cases:15.38%
controls:1.36%
cases:38.41%
controls:9.48%
cases:42.76%
controls:23.20%
79
488
91
1209
50
158
120
1539
19
19
151
1678
—
26
23
143
1668
63
158
101
1509
62
360
83
1192
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
19072-8 [3016431]
8.1e-01
1.4e+00
3.1e+00
—
2.2e+00
1.7e+00
1.0e+00
cases:8.82%
controls:4.12%
cases:10.00%
controls:2.77%
cases:7.06%
controls:0.35%
—
—
cases:5.33%
controls:0.59%
cases:11.59%
controls:2.34%
cases:21.38%
controls:8.76%
15
70
155
1627
17
47
153
1650
12
6
158
1691
—
9
10
160
1681
19
39
145
1628
31
136
114
1416
pantoprazole; oral, parenteral
A02BC02 [21600097]
A02BC02 [21600097]
7.8e-01
1.2e+00
1.8e+00
—
2.5e+00
1.7e+00
1.1e+00
cases:23.53%
controls:12.37%
cases:21.18%
controls:7.25%
cases:7.65%
controls:1.36%
—
—
cases:14.20%
controls:1.30%
cases:26.83%
controls:6.54%
cases:35.86%
controls:16.17%
40
210
130
1487
36
123
134
1574
13
23
157
1674
—
24
22
145
1669
44
109
120
1558
52
251
93
1301
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6768-6 [3035995]
2.1e-01
1.0e+00
2.9e+00
1.0e+50
2.2e+00
1.7e+00
1.3e+00
cases:11.76%
controls:9.78%
cases:15.88%
controls:6.42%
cases:13.53%
controls:0.88%
cases:2.94%
controls:0.00%
cases:9.47%
controls:1.18%
cases:24.39%
controls:5.82%
cases:40.00%
controls:15.72%
20
166
150
1531
27
109
143
1588
23
15
147
1682
5
0
165
1697
16
20
153
1671
40
97
124
1570
58
244
87
1308
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1995-0 [3021347]
7.0e-01
1.2e+00
2.9e+00
—
2.1e+00
1.7e+00
1.2e+00
cases:7.65%
controls:3.95%
cases:7.65%
controls:2.53%
cases:5.88%
controls:0.35%
—
—
cases:5.33%
controls:0.71%
cases:10.37%
controls:2.16%
cases:20.69%
controls:7.15%
13
67
157
1630
13
43
157
1654
10
6
160
1691
—
9
12
160
1679
17
36
147
1631
30
111
115
1441
Outpatient Hospital
22 [8756]
22 [8756]
5.7e-01
1.3e+00
2.2e+00
—
2.8e+00
1.6e+00
9.6e-01
cases:34.71%
controls:23.16%
cases:18.82%
controls:6.13%
cases:5.29%
controls:0.59%
—
—
cases:9.47%
controls:0.65%
cases:25.00%
controls:6.24%
cases:37.93%
controls:18.94%
59
393
111
1304
32
104
138
1593
9
10
161
1687
—
16
11
153
1680
41
104
123
1563
55
294
90
1258
Normoblasts [#/volume] in Blood
715-3 [3021589]
715-3 [3021589]
-4.8e-02
9.6e-01
2.5e+00
—
2.0e+00
1.6e+00
1.4e+00
cases:5.29%
controls:5.54%
cases:11.18%
controls:4.60%
cases:12.35%
controls:1.12%
—
—
cases:7.10%
controls:1.01%
cases:17.07%
controls:4.02%
cases:26.90%
controls:8.38%
9
94
161
1603
19
78
151
1619
21
19
149
1678
—
12
17
157
1674
28
67
136
1600
39
130
106
1422
alendronic acid; oral
M05BA04 [21604152]
M05BA04 [21604152]
2.0e+00
—
—
—
—
3.3e+00
2.9e+00
cases:6.47%
controls:0.88%
—
—
—
—
—
—
—
—
cases:9.15%
controls:0.36%
cases:13.79%
controls:0.84%
11
15
159
1682
—
—
—
—
15
6
149
1661
20
13
125
1539
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
24357-6 [3037467]
4.1e-01
1.3e+00
3.1e+00
—
1.7e+00
1.2e+00
9.8e-01
cases:12.35%
controls:8.54%
cases:14.71%
controls:4.42%
cases:10.59%
controls:0.53%
—
—
cases:4.73%
controls:0.89%
cases:16.46%
controls:5.76%
cases:31.72%
controls:14.82%
21
145
149
1552
25
75
145
1622
18
9
152
1688
—
8
15
161
1676
27
96
137
1571
46
230
99
1322
Neurology
13 [38004458]
13 [38004458]
1.1e+00
1.6e+00
2.3e+00
1.0e+50
1.9e+00
2.0e+00
1.2e+00
cases:18.82%
controls:7.25%
cases:14.12%
controls:3.12%
cases:5.29%
controls:0.53%
cases:7.06%
controls:0.00%
cases:2.96%
controls:0.47%
cases:18.29%
controls:3.06%
cases:25.52%
controls:9.09%
32
123
138
1574
24
53
146
1644
9
9
161
1688
12
0
158
1697
5
8
164
1683
30
51
134
1616
37
141
108
1411
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
2157-6 [3007220]
8.8e-01
2.5e+00
—
1.0e+50
—
3.0e+00
2.7e+00
cases:7.06%
controls:3.06%
cases:17.06%
controls:1.59%
—
—
cases:5.29%
controls:0.00%
—
—
cases:21.34%
controls:1.38%
cases:37.93%
controls:3.87%
12
52
158
1645
29
27
141
1670
—
9
0
161
1697
—
35
23
129
1644
55
60
90
1492
Physiotherapist
Z3226 [2001311560]
Z3226 [2001311560]
1.3e+00
2.3e+00
—
1.0e+50
—
2.5e+00
1.8e+00
cases:7.06%
controls:2.06%
cases:4.71%
controls:0.47%
—
—
cases:2.94%
controls:0.00%
—
—
cases:6.71%
controls:0.60%
cases:13.10%
controls:2.32%
12
35
158
1662
8
8
162
1689
—
5
0
165
1697
—
11
10
153
1657
19
36
126
1516
Pharmacy visit
OMOP4822462 [581458]
OMOP4822462 [581458]
-2.9e-02
1.0e+00
1.3e+00
2.6e+00
1.5e+00
1.5e+00
1.0e+00
cases:89.41%
controls:89.69%
cases:91.76%
controls:79.67%
cases:70.59%
controls:40.19%
cases:19.41%
controls:1.71%
cases:75.15%
controls:40.21%
cases:94.51%
controls:79.66%
cases:97.93%
controls:94.39%
152
1522
18
175
156
1352
14
345
120
682
50
1015
33
29
137
1668
127
680
42
1011
155
1328
9
339
142
1465
3
87
hydrocortisone
S02BA01 [21605166]
S02BA01 [21605166]
4.3e-01
2.3e+00
3.1e+00
—
—
2.1e+00
3.4e-01
cases:9.41%
controls:6.31%
cases:14.71%
controls:1.77%
cases:6.47%
controls:0.29%
—
—
—
—
cases:10.98%
controls:1.50%
cases:7.59%
controls:5.54%
16
107
154
1590
25
30
145
1667
11
5
159
1692
—
—
18
25
146
1642
11
86
134
1466
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
2465-3 [3005719]
1.8e+00
2.7e+00
1.0e+50
—
1.0e+50
—
3.0e+00
cases:4.12%
controls:0.71%
cases:4.12%
controls:0.29%
cases:3.53%
controls:0.00%
—
—
cases:5.33%
controls:0.00%
—
—
cases:15.17%
controls:0.90%
7
12
163
1685
7
5
163
1692
6
0
164
1697
—
9
0
160
1691
—
22
14
123
1538
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1751-7 [3024561]
6.4e-01
8.9e-01
2.6e+00
—
2.5e+00
1.3e+00
1.0e+00
cases:8.24%
controls:4.54%
cases:6.47%
controls:2.77%
cases:4.71%
controls:0.35%
—
—
cases:4.73%
controls:0.41%
cases:7.32%
controls:2.04%
cases:16.55%
controls:6.83%
14
77
156
1620
11
47
159
1650
8
6
162
1691
—
8
7
161
1684
12
34
152
1633
24
106
121
1446
Thorax X-ray examination
GD1AA [2001303617]
GD1AA [2001303617]
1.1e+00
2.1e+00
—
—
—
2.5e+00
1.7e+00
cases:14.12%
controls:5.42%
cases:12.94%
controls:1.71%
—
—
—
—
—
—
cases:17.68%
controls:1.74%
cases:26.21%
controls:6.12%
24
92
146
1605
22
29
148
1668
—
—
—
29
29
135
1638
38
95
107
1457
Physiotherapy
R4110 [2001310233]
R4110 [2001310233]
1.1e+00
2.0e+00
—
1.0e+50
—
2.5e+00
1.8e+00
cases:10.00%
controls:3.48%
cases:7.06%
controls:1.06%
—
—
cases:4.71%
controls:0.00%
—
—
cases:14.02%
controls:1.32%
cases:17.24%
controls:3.35%
17
59
153
1638
12
18
158
1679
—
8
0
162
1697
—
23
22
141
1645
25
52
120
1500
hydrocortisone aceponate
D07AC16 [21602135]
D07AC16 [21602135]
5.4e-01
2.1e+00
3.1e+00
—
—
2.1e+00
5.8e-01
cases:11.76%
controls:7.19%
cases:15.29%
controls:2.06%
cases:7.06%
controls:0.35%
—
—
—
—
cases:12.20%
controls:1.62%
cases:10.34%
controls:6.06%
20
122
150
1575
26
35
144
1662
12
6
158
1691
—
—
20
27
144
1640
15
94
130
1458
hydrocortisone buteprate
D07AB11 [21602115]
D07AB11 [21602115]
5.4e-01
2.1e+00
3.1e+00
—
—
2.1e+00
5.8e-01
cases:11.76%
controls:7.19%
cases:15.29%
controls:2.06%
cases:7.06%
controls:0.35%
—
—
—
—
cases:12.20%
controls:1.62%
cases:10.34%
controls:6.06%
20
122
150
1575
26
35
144
1662
12
6
158
1691
—
—
20
27
144
1640
15
94
130
1458
hydrocortisone butyrate
D07AB02 [21602106]
D07AB02 [21602106]
5.4e-01
2.1e+00
3.1e+00
—
—
2.1e+00
5.8e-01
cases:11.76%
controls:7.19%
cases:15.29%
controls:2.06%
cases:7.06%
controls:0.35%
—
—
—
—
cases:12.20%
controls:1.62%
cases:10.34%
controls:6.06%
20
122
150
1575
26
35
144
1662
12
6
158
1691
—
—
20
27
144
1640
15
94
130
1458
hydrocortisone
D07AA02 [21602102]
D07AA02 [21602102]
5.4e-01
2.1e+00
3.1e+00
—
—
2.1e+00
5.8e-01
cases:11.76%
controls:7.19%
cases:15.29%
controls:2.06%
cases:7.06%
controls:0.35%
—
—
—
—
cases:12.20%
controls:1.62%
cases:10.34%
controls:6.06%
20
122
150
1575
26
35
144
1662
12
6
158
1691
—
—
20
27
144
1640
15
94
130
1458
betamethasone
D07AC01 [21602120]
D07AC01 [21602120]
6.5e-01
2.3e+00
3.1e+00
—
2.3e+00
1.9e+00
7.7e-01
cases:9.41%
controls:5.13%
cases:20.59%
controls:2.59%
cases:6.47%
controls:0.29%
—
—
cases:2.96%
controls:0.30%
cases:12.20%
controls:2.04%
cases:14.48%
controls:7.28%
16
87
154
1610
35
44
135
1653
11
5
159
1692
—
5
5
164
1686
20
34
144
1633
21
113
124
1439
betamethasone
S02BA07 [21605169]
S02BA07 [21605169]
6.5e-01
2.3e+00
3.1e+00
—
2.3e+00
1.9e+00
7.7e-01
cases:9.41%
controls:5.13%
cases:20.59%
controls:2.59%
cases:6.47%
controls:0.29%
—
—
cases:2.96%
controls:0.30%
cases:12.20%
controls:2.04%
cases:14.48%
controls:7.28%
16
87
154
1610
35
44
135
1653
11
5
159
1692
—
5
5
164
1686
20
34
144
1633
21
113
124
1439
betamethasone
C05AA05 [21601610]
C05AA05 [21601610]
6.5e-01
2.3e+00
3.1e+00
—
2.3e+00
1.9e+00
7.7e-01
cases:9.41%
controls:5.13%
cases:20.59%
controls:2.59%
cases:6.47%
controls:0.29%
—
—
cases:2.96%
controls:0.30%
cases:12.20%
controls:2.04%
cases:14.48%
controls:7.28%
16
87
154
1610
35
44
135
1653
11
5
159
1692
—
5
5
164
1686
20
34
144
1633
21
113
124
1439
betamethasone
A07EA04 [21600656]
A07EA04 [21600656]
6.5e-01
2.3e+00
3.1e+00
—
2.3e+00
1.9e+00
7.7e-01
cases:9.41%
controls:5.13%
cases:20.59%
controls:2.59%
cases:6.47%
controls:0.29%
—
—
cases:2.96%
controls:0.30%
cases:12.20%
controls:2.04%
cases:14.48%
controls:7.28%
16
87
154
1610
35
44
135
1653
11
5
159
1692
—
5
5
164
1686
20
34
144
1633
21
113
124
1439
desonide
D07AB08 [21602112]
D07AB08 [21602112]
—
2.6e+00
—
—
—
3.0e+00
1.7e+00
—
—
cases:7.65%
controls:0.59%
—
—
—
—
—
—
cases:5.49%
controls:0.30%
cases:6.21%
controls:1.16%
—
13
10
157
1687
—
—
—
9
5
155
1662
9
18
136
1534
hydrocortisone
A07EA02 [21600654]
A07EA02 [21600654]
5.3e-01
2.1e+00
3.1e+00
—
—
2.1e+00
5.6e-01
cases:11.76%
controls:7.31%
cases:15.29%
controls:2.06%
cases:7.06%
controls:0.35%
—
—
—
—
cases:12.20%
controls:1.68%
cases:10.34%
controls:6.19%
20
124
150
1573
26
35
144
1662
12
6
158
1691
—
—
20
28
144
1639
15
96
130
1456
hydrocortisone
C05AA01 [21601608]
C05AA01 [21601608]
5.3e-01
2.1e+00
3.1e+00
—
—
2.1e+00
5.6e-01
cases:11.76%
controls:7.31%
cases:15.29%
controls:2.06%
cases:7.06%
controls:0.35%
—
—
—
—
cases:12.20%
controls:1.68%
cases:10.34%
controls:6.19%
20
124
150
1573
26
35
144
1662
12
6
158
1691
—
—
20
28
144
1639
15
96
130
1456
Emergency Room Visit
ER [9203]
ER [9203]
4.4e-01
8.9e-01
2.5e+00
—
1.9e+00
1.2e+00
7.7e-01
cases:38.82%
controls:28.99%
cases:22.35%
controls:10.55%
cases:9.41%
controls:0.88%
—
—
cases:5.92%
controls:0.89%
cases:26.22%
controls:9.42%
cases:44.14%
controls:26.74%
66
492
104
1205
38
179
132
1518
16
15
154
1682
—
10
15
159
1676
43
157
121
1510
64
415
81
1137
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
29953-7 [3037522]
1.5e+00
3.2e+00
—
—
—
2.0e+00
2.3e+00
cases:5.29%
controls:1.18%
cases:12.35%
controls:0.59%
—
—
—
—
—
—
cases:3.05%
controls:0.42%
cases:13.79%
controls:1.61%
9
20
161
1677
21
10
149
1687
—
—
—
5
7
159
1660
20
25
125
1527
pH of Serum or Plasma
2753-2 [3018418]
2753-2 [3018418]
1.2e+00
1.2e+00
2.6e+00
—
1.9e+00
1.7e+00
1.3e+00
cases:7.65%
controls:2.53%
cases:5.88%
controls:1.83%
cases:4.71%
controls:0.35%
—
—
cases:2.96%
controls:0.47%
cases:9.15%
controls:1.80%
cases:17.24%
controls:5.22%
13
43
157
1654
10
31
160
1666
8
6
162
1691
—
5
8
164
1683
15
30
149
1637
25
81
120
1471
Short blood count panel - Blood
55429-5 [40758558]
55429-5 [40758558]
7.5e-02
1.1e+00
3.0e+00
—
—
2.4e+00
1.4e+00
cases:4.12%
controls:3.83%
cases:5.88%
controls:2.00%
cases:7.65%
controls:0.41%
—
—
—
—
cases:9.76%
controls:0.96%
cases:16.55%
controls:4.83%
7
65
163
1632
10
34
160
1663
13
7
157
1690
—
—
16
16
148
1651
24
75
121
1477
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
1988-5 [3020460]
2.0e-01
8.0e-01
2.2e+00
—
1.7e+00
1.0e+00
8.1e-01
cases:18.82%
controls:15.91%
cases:22.94%
controls:11.79%
cases:15.88%
controls:2.06%
—
—
cases:10.65%
controls:2.07%
cases:25.61%
controls:11.16%
cases:45.52%
controls:27.00%
32
270
138
1427
39
200
131
1497
27
35
143
1662
—
18
35
151
1656
42
186
122
1481
66
419
79
1133
Platelets [#/volume] in Blood
26515-7 [3007461]
26515-7 [3007461]
9.5e-02
4.3e-01
1.7e+00
3.2e+00
1.5e+00
5.5e-01
4.2e-01
cases:23.53%
controls:21.86%
cases:25.88%
controls:18.56%
cases:19.41%
controls:4.24%
cases:7.06%
controls:0.29%
cases:14.79%
controls:3.61%
cases:29.88%
controls:19.80%
cases:48.97%
controls:38.72%
40
371
130
1326
44
315
126
1382
33
72
137
1625
12
5
158
1692
25
61
144
1630
49
330
115
1337
71
601
74
951
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
30428-7 [3024731]
8.8e-02
4.6e-01
1.7e+00
3.2e+00
1.5e+00
5.5e-01
4.2e-01
cases:23.53%
controls:21.98%
cases:26.47%
controls:18.56%
cases:19.41%
controls:4.30%
cases:7.06%
controls:0.29%
cases:14.79%
controls:3.61%
cases:29.88%
controls:19.80%
cases:48.97%
controls:38.72%
40
373
130
1324
45
315
125
1382
33
73
137
1624
12
5
158
1692
25
61
144
1630
49
330
115
1337
71
601
74
951
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
20570-8 [3009542]
8.8e-02
4.5e-01
1.7e+00
3.2e+00
1.5e+00
5.4e-01
4.2e-01
cases:23.53%
controls:21.98%
cases:26.47%
controls:18.62%
cases:19.41%
controls:4.30%
cases:7.06%
controls:0.29%
cases:14.79%
controls:3.61%
cases:29.88%
controls:19.86%
cases:48.97%
controls:38.72%
40
373
130
1324
45
316
125
1381
33
73
137
1624
12
5
158
1692
25
61
144
1630
49
331
115
1336
71
601
74
951
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
718-7 [3000963]
8.1e-02
4.6e-01
1.7e+00
3.2e+00
1.5e+00
5.5e-01
4.2e-01
cases:23.53%
controls:22.10%
cases:26.47%
controls:18.56%
cases:19.41%
controls:4.30%
cases:7.06%
controls:0.29%
cases:14.79%
controls:3.61%
cases:29.88%
controls:19.80%
cases:48.97%
controls:38.72%
40
375
130
1322
45
315
125
1382
33
73
137
1624
12
5
158
1692
25
61
144
1630
49
330
115
1337
71
601
74
951
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
26453-1 [3026361]
5.5e-02
4.6e-01
1.7e+00
3.2e+00
1.5e+00
5.5e-01
4.2e-01
cases:22.94%
controls:21.98%
cases:26.47%
controls:18.56%
cases:19.41%
controls:4.30%
cases:7.06%
controls:0.29%
cases:14.79%
controls:3.61%
cases:29.88%
controls:19.80%
cases:48.97%
controls:38.72%
39
373
131
1324
45
315
125
1382
33
73
137
1624
12
5
158
1692
25
61
144
1630
49
330
115
1337
71
601
74
951
Leukocytes [#/volume] in Blood
26464-8 [3010813]
26464-8 [3010813]
8.5e-02
4.6e-01
1.7e+00
3.2e+00
1.5e+00
5.4e-01
4.1e-01
cases:23.53%
controls:22.04%
cases:26.47%
controls:18.56%
cases:19.41%
controls:4.30%
cases:7.06%
controls:0.29%
cases:14.79%
controls:3.61%
cases:29.88%
controls:19.86%
cases:48.97%
controls:38.79%
40
374
130
1323
45
315
125
1382
33
73
137
1624
12
5
158
1692
25
61
144
1630
49
331
115
1336
71
602
74
950
MCH [Entitic mass]
28539-5 [3035941]
28539-5 [3035941]
5.5e-02
4.6e-01
1.7e+00
3.2e+00
1.5e+00
5.5e-01
4.2e-01
cases:22.94%
controls:21.98%
cases:26.47%
controls:18.56%
cases:19.41%
controls:4.30%
cases:7.06%
controls:0.29%
cases:14.79%
controls:3.61%
cases:29.88%
controls:19.80%
cases:48.97%
controls:38.72%
39
373
131
1324
45
315
125
1382
33
73
137
1624
12
5
158
1692
25
61
144
1630
49
330
115
1337
71
601
74
951
Laboratory Visit
OMOP4822461 [32036]
OMOP4822461 [32036]
-1.5e-02
3.2e-01
1.3e+00
3.5e+00
1.5e+00
2.9e-01
2.0e-01
cases:24.71%
controls:24.99%
cases:30.59%
controls:24.28%
cases:23.53%
controls:7.54%
cases:11.76%
controls:0.41%
cases:24.26%
controls:6.68%
cases:31.71%
controls:25.85%
cases:48.97%
controls:44.07%
42
424
128
1273
52
412
118
1285
40
128
130
1569
20
7
150
1690
41
113
128
1578
52
431
112
1236
71
684
74
868
mometasone
D07AC13 [21602132]
D07AC13 [21602132]
1.0e+00
2.3e+00
—
—
—
2.0e+00
1.0e+00
cases:10.59%
controls:4.18%
cases:15.88%
controls:1.94%
—
—
—
—
—
—
cases:9.76%
controls:1.50%
cases:11.03%
controls:4.32%
18
71
152
1626
27
33
143
1664
—
—
—
16
25
148
1642
16
67
129
1485
Gastroenterology
10 [38004455]
10 [38004455]
1.3e+00
1.6e+00
—
—
—
1.9e+00
1.4e+00
cases:12.35%
controls:3.54%
cases:7.65%
controls:1.65%
—
—
—
—
—
—
cases:9.76%
controls:1.56%
cases:14.48%
controls:4.19%
21
60
149
1637
13
28
157
1669
—
—
—
16
26
148
1641
21
65
124
1487
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
2601-3 [3012095]
1.2e+00
2.3e+00
—
—
—
2.3e+00
1.5e+00
cases:4.71%
controls:1.41%
cases:5.29%
controls:0.53%
—
—
—
—
—
—
cases:5.49%
controls:0.60%
cases:7.59%
controls:1.87%
8
24
162
1673
9
9
161
1688
—
—
—
9
10
155
1657
11
29
134
1523
lansoprazole; oral
A02BC03 [21600098]
A02BC03 [21600098]
1.1e+00
1.4e+00
—
—
—
2.0e+00
1.4e+00
cases:11.18%
controls:4.01%
cases:6.47%
controls:1.71%
—
—
—
—
—
—
cases:11.59%
controls:1.74%
cases:13.79%
controls:3.93%
19
68
151
1629
11
29
159
1668
—
—
—
19
29
145
1638
20
61
125
1491
omeprazole; oral, parenteral
A02BC01 [21600096]
A02BC01 [21600096]
6.1e-01
1.0e+00
—
—
2.6e+00
2.0e+00
1.3e+00
cases:7.06%
controls:3.95%
cases:4.12%
controls:1.53%
—
—
—
—
cases:4.73%
controls:0.35%
cases:9.76%
controls:1.50%
cases:11.03%
controls:3.41%
12
67
158
1630
7
26
163
1671
—
—
8
6
161
1685
16
25
148
1642
16
53
129
1499
Connective tissue diseases, rheumatoid arthritis and comparable disease
202 [2001600200]
202 [2001600200]
3.4e+00
—
—
—
—
—
2.3e+00
cases:12.94%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.45%
22
8
148
1689
—
—
—
—
—
6
7
139
1545
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
2458-8 [3007164]
1.4e+00
2.2e+00
—
—
—
2.0e+00
9.2e-01
cases:8.24%
controls:2.24%
cases:5.29%
controls:0.59%
—
—
—
—
—
—
cases:4.27%
controls:0.60%
cases:7.59%
controls:3.16%
14
38
156
1659
9
10
161
1687
—
—
—
7
10
157
1657
11
49
134
1503
Case Management Agency
251B00000X [38004193]
251B00000X [38004193]
3.1e-01
3.8e-01
8.9e-01
3.8e+00
9.0e-01
5.1e-01
1.9e-01
cases:54.12%
controls:46.38%
cases:48.24%
controls:38.89%
cases:28.82%
controls:14.32%
cases:19.41%
controls:0.53%
cases:31.36%
controls:15.73%
cases:54.88%
controls:42.23%
cases:73.10%
controls:69.27%
92
787
78
910
82
660
88
1037
49
243
121
1454
33
9
137
1688
53
266
116
1425
90
704
74
963
106
1075
39
477
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
NK6QA [2001308500]
2.3e+00
—
—
—
—
1.0e+50
3.2e+00
cases:4.12%
controls:0.41%
—
—
—
—
—
—
—
—
cases:3.05%
controls:0.00%
cases:10.34%
controls:0.45%
7
7
163
1690
—
—
—
—
5
0
159
1667
15
7
130
1545
Medical doctor
Z2221 [2001311556]
Z2221 [2001311556]
1.0e+00
1.7e+00
—
1.0e+50
—
2.2e+00
1.6e+00
cases:8.82%
controls:3.42%
cases:8.82%
controls:1.71%
—
—
cases:4.71%
controls:0.00%
—
—
cases:10.98%
controls:1.38%
cases:13.79%
controls:3.22%
15
58
155
1639
15
29
155
1668
—
8
0
162
1697
—
18
23
146
1644
20
50
125
1502
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
50554-5 [3029287]
5.7e-01
1.3e+00
2.7e+00
—
1.8e+00
1.5e+00
7.3e-01
cases:7.06%
controls:4.12%
cases:7.65%
controls:2.24%
cases:4.12%
controls:0.29%
—
—
cases:3.55%
controls:0.59%
cases:8.54%
controls:2.10%
cases:11.72%
controls:5.99%
12
70
158
1627
13
38
157
1659
7
5
163
1692
—
6
10
163
1681
14
35
150
1632
17
93
128
1459
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
30385-9 [3002385]
7.9e-02
4.9e-01
2.0e+00
—
1.6e+00
8.5e-01
7.3e-01
cases:15.88%
controls:14.85%
cases:18.24%
controls:12.02%
cases:15.88%
controls:2.42%
—
—
cases:10.65%
controls:2.25%
cases:24.39%
controls:12.12%
cases:40.69%
controls:24.94%
27
252
143
1445
31
204
139
1493
27
41
143
1656
—
18
38
151
1653
40
202
124
1465
59
387
86
1165
Leukocytes [#/volume] in Urine
30405-5 [3018095]
30405-5 [3018095]
5.8e-01
1.6e+00
2.6e+00
—
1.8e+00
1.2e+00
9.7e-01
cases:6.47%
controls:3.71%
cases:8.82%
controls:2.00%
cases:4.71%
controls:0.35%
—
—
cases:3.55%
controls:0.59%
cases:7.32%
controls:2.28%
cases:16.55%
controls:7.02%
11
63
159
1634
15
34
155
1663
8
6
162
1691
—
6
10
163
1681
12
38
152
1629
24
109
121
1443
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
1742-6 [3006923]
1.9e-01
4.8e-01
2.1e+00
—
2.2e+00
8.9e-01
4.6e-01
cases:21.18%
controls:18.21%
cases:20.59%
controls:13.85%
cases:17.06%
controls:2.53%
—
—
cases:15.38%
controls:2.07%
cases:29.27%
controls:14.52%
cases:44.83%
controls:33.89%
36
309
134
1388
35
235
135
1462
29
43
141
1654
—
26
35
143
1656
48
242
116
1425
65
526
80
1026
betamethasone
S03BA03 [21605203]
S03BA03 [21605203]
1.4e+00
2.7e+00
—
—
—
2.2e+00
6.6e-01
cases:5.29%
controls:1.41%
cases:7.65%
controls:0.53%
—
—
—
—
—
—
cases:3.66%
controls:0.42%
cases:4.14%
controls:2.19%
9
24
161
1673
13
9
157
1688
—
—
—
6
7
158
1660
6
34
139
1518
esomeprazole; oral, parenteral
A02BC05 [21600100]
A02BC05 [21600100]
9.6e-01
1.4e+00
1.6e+00
—
1.3e+00
1.6e+00
9.3e-01
cases:18.24%
controls:7.84%
cases:12.35%
controls:3.42%
cases:3.53%
controls:0.71%
—
—
cases:3.55%
controls:0.95%
cases:15.24%
controls:3.66%
cases:18.62%
controls:8.25%
31
133
139
1564
21
58
149
1639
6
12
164
1685
—
6
16
163
1675
25
61
139
1606
27
128
118
1424
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
14749-6 [3013826]
1.8e-01
4.2e-01
1.8e+00
—
1.8e+00
1.2e+00
4.4e-01
cases:6.47%
controls:5.48%
cases:5.29%
controls:3.54%
cases:4.71%
controls:0.82%
—
—
cases:4.14%
controls:0.71%
cases:9.15%
controls:2.88%
cases:13.79%
controls:9.34%
11
93
159
1604
9
60
161
1637
8
14
162
1683
—
7
12
162
1679
15
48
149
1619
20
145
125
1407
methylprednisolone; oral, parenteral
H02AB04 [21602732]
H02AB04 [21602732]
6.3e-01
2.3e+00
—
—
—
2.4e+00
1.4e+00
cases:2.94%
controls:1.59%
cases:4.12%
controls:0.41%
—
—
—
—
—
—
cases:4.27%
controls:0.42%
cases:4.14%
controls:1.10%
5
27
165
1670
7
7
163
1690
—
—
—
7
7
157
1660
6
17
139
1535
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
UJD10 [2001304788]
1.4e+00
1.2e+00
—
—
1.0e+50
1.9e+00
1.3e+00
cases:12.35%
controls:3.42%
cases:3.53%
controls:1.06%
—
—
—
—
cases:3.55%
controls:0.00%
cases:6.71%
controls:1.08%
cases:10.34%
controls:3.09%
21
58
149
1639
6
18
164
1679
—
—
6
0
163
1691
11
18
153
1649
15
48
130
1504
Intravenous
ZX120 [2001311495]
ZX120 [2001311495]
2.0e+00
—
—
—
—
—
2.5e+00
cases:4.12%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
cases:10.34%
controls:0.90%
7
10
163
1687
—
—
—
—
—
15
14
130
1538
Spirometry study
18759-1 [3000492]
18759-1 [3000492]
—
2.5e+00
—
—
—
—
1.9e+00
—
—
cases:3.53%
controls:0.29%
—
—
—
—
—
—
—
—
cases:6.21%
controls:0.97%
—
6
5
164
1692
—
—
—
—
9
15
136
1537
More than one and less than three hours
ZXE10 [2001311401]
ZXE10 [2001311401]
1.0e+00
—
—
—
—
2.1e+00
1.2e+00
cases:12.94%
controls:5.07%
—
—
—
—
—
—
—
—
cases:6.71%
controls:0.90%
cases:12.41%
controls:3.99%
22
86
148
1611
—
—
—
—
11
15
153
1652
18
62
127
1490
furosemide; oral, parenteral
C03CA01 [21601518]
C03CA01 [21601518]
1.0e+00
1.5e+00
1.4e+00
—
—
1.5e+00
1.2e+00
cases:8.82%
controls:3.42%
cases:10.59%
controls:2.47%
cases:2.94%
controls:0.77%
—
—
—
—
cases:9.76%
controls:2.28%
cases:13.79%
controls:4.51%
15
58
155
1639
18
42
152
1655
5
13
165
1684
—
—
16
38
148
1629
20
70
125
1482
Abdominal ultrasound examination
JN3AE [2001305555]
JN3AE [2001305555]
—
2.1e+00
—
1.0e+50
—
—
2.2e+00
—
—
cases:4.12%
controls:0.53%
—
—
cases:2.94%
controls:0.00%
—
—
—
—
cases:6.90%
controls:0.84%
—
7
9
163
1688
—
5
0
165
1697
—
—
10
13
135
1539
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
14682-9 [3020564]
1.6e-01
4.2e-01
1.7e+00
—
1.8e+00
7.6e-01
4.4e-01
cases:21.76%
controls:19.15%
cases:22.35%
controls:15.97%
cases:17.65%
controls:3.65%
—
—
cases:15.98%
controls:3.19%
cases:29.88%
controls:16.56%
cases:46.21%
controls:35.63%
37
325
133
1372
38
271
132
1426
30
62
140
1635
—
27
54
142
1637
49
276
115
1391
67
553
78
999
combinations of corticosteroids
D07AB30 [21602118]
D07AB30 [21602118]
4.8e-01
1.9e+00
2.3e+00
—
—
5.5e-01
4.3e-01
cases:14.71%
controls:9.66%
cases:17.06%
controls:2.95%
cases:3.53%
controls:0.35%
—
—
—
—
cases:4.88%
controls:2.88%
cases:15.86%
controls:10.95%
25
164
145
1533
29
50
141
1647
6
6
164
1691
—
—
8
48
156
1619
23
170
122
1382
combinations of corticosteroids
D07XB30 [21602188]
D07XB30 [21602188]
4.8e-01
1.9e+00
2.3e+00
—
—
5.5e-01
4.3e-01
cases:14.71%
controls:9.66%
cases:17.06%
controls:2.95%
cases:3.53%
controls:0.35%
—
—
—
—
cases:4.88%
controls:2.88%
cases:15.86%
controls:10.95%
25
164
145
1533
29
50
141
1647
6
6
164
1691
—
—
8
48
156
1619
23
170
122
1382
Fever, unspecified
R50.9 [45582716]
R50.9 [45582716]
1.3e+00
2.0e+00
—
—
—
2.1e+00
1.0e+00
cases:4.12%
controls:1.18%
cases:4.71%
controls:0.65%
—
—
—
—
—
—
cases:4.27%
controls:0.54%
cases:3.45%
controls:1.29%
7
20
163
1677
8
11
162
1686
—
—
—
7
9
157
1658
5
20
140
1532
Cathetrisation of vein
TPH04 [2001309597]
TPH04 [2001309597]
1.5e+00
2.3e+00
—
—
—
2.6e+00
1.1e+00
cases:8.24%
controls:1.89%
cases:2.94%
controls:0.29%
—
—
—
—
—
—
cases:6.71%
controls:0.54%
cases:6.90%
controls:2.38%
14
32
156
1665
5
5
165
1692
—
—
—
11
9
153
1658
10
37
135
1515
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
30391-7 [3002582]
5.7e-01
1.5e+00
2.5e+00
—
1.7e+00
1.2e+00
8.5e-01
cases:6.47%
controls:3.77%
cases:7.65%
controls:1.83%
cases:3.53%
controls:0.29%
—
—
cases:2.96%
controls:0.53%
cases:6.10%
controls:1.98%
cases:12.41%
controls:5.73%
11
64
159
1633
13
31
157
1666
6
5
164
1692
—
5
9
164
1682
10
33
154
1634
18
89
127
1463
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
2472-9 [3028026]
2.0e+00
—
—
—
1.0e+50
—
1.9e+00
cases:3.53%
controls:0.47%
—
—
—
—
—
—
cases:2.96%
controls:0.00%
—
—
cases:5.52%
controls:0.84%
6
8
164
1689
—
—
—
5
0
164
1691
—
8
13
137
1539
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
16128-1 [3017143]
9.4e-01
—
—
—
—
2.3e+00
1.6e+00
cases:3.53%
controls:1.41%
—
—
—
—
—
—
—
—
cases:3.66%
controls:0.36%
cases:5.52%
controls:1.16%
6
24
164
1673
—
—
—
—
6
6
158
1661
8
18
137
1534
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
5802-4 [3021601]
5.1e-01
9.8e-01
3.1e+00
—
1.4e+00
9.4e-01
7.5e-01
cases:8.24%
controls:5.13%
cases:7.65%
controls:3.01%
cases:6.47%
controls:0.29%
—
—
cases:2.96%
controls:0.77%
cases:9.15%
controls:3.78%
cases:21.38%
controls:11.34%
14
87
156
1610
13
51
157
1646
11
5
159
1692
—
5
13
164
1678
15
63
149
1604
31
176
114
1376
Physical Medicine And Rehabilitation
25 [38004468]
25 [38004468]
4.9e-01
1.1e+00
—
—
—
2.5e+00
1.4e+00
cases:8.82%
controls:5.60%
cases:3.53%
controls:1.18%
—
—
—
—
—
—
cases:14.63%
controls:1.44%
cases:20.69%
controls:6.19%
15
95
155
1602
6
20
164
1677
—
—
—
24
24
140
1643
30
96
115
1456
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2514-8 [3035350]
4.0e-01
1.0e+00
3.0e+00
—
1.4e+00
9.8e-01
7.4e-01
cases:7.65%
controls:5.24%
cases:7.65%
controls:2.95%
cases:5.88%
controls:0.29%
—
—
cases:2.96%
controls:0.77%
cases:9.76%
controls:3.90%
cases:21.38%
controls:11.47%
13
89
157
1608
13
50
157
1647
10
5
160
1692
—
5
13
164
1678
16
65
148
1602
31
178
114
1374
Dermatitis, unspecified
L30.9 [45572271]
L30.9 [45572271]
—
3.7e+00
—
—
1.0e+50
—
1.0e+00
—
—
cases:12.35%
controls:0.35%
—
—
—
—
cases:2.96%
controls:0.00%
—
—
cases:6.90%
controls:2.58%
—
21
6
149
1691
—
—
5
0
164
1691
—
10
40
135
1512
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
NK4XE [2001308469]
—
—
—
—
—
—
3.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.10%
controls:0.45%
—
—
—
—
—
—
19
7
126
1545
Myoglobin [Mass/volume] in Serum or Plasma
2639-3 [3005895]
2639-3 [3005895]
—
—
—
—
1.0e+50
—
3.4e+00
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.00%
—
—
cases:8.97%
controls:0.32%
—
—
—
—
7
0
162
1691
—
13
5
132
1547
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
28540-3 [3003338]
1.3e-01
5.1e-01
1.8e+00
—
1.6e+00
6.2e-01
4.5e-01
cases:18.24%
controls:16.38%
cases:19.41%
controls:12.67%
cases:14.12%
controls:2.71%
—
—
cases:10.65%
controls:2.37%
cases:21.95%
controls:13.14%
cases:38.62%
controls:28.61%
31
278
139
1419
33
215
137
1482
24
46
146
1651
—
18
40
151
1651
36
219
128
1448
56
444
89
1108
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
31017-7 [3019050]
1.2e+00
2.1e+00
—
—
—
—
4.6e-01
cases:8.24%
controls:2.53%
cases:4.71%
controls:0.59%
—
—
—
—
—
—
—
—
cases:5.52%
controls:3.54%
14
43
156
1654
8
10
162
1687
—
—
—
—
8
55
137
1497
Pneumonia, unspecified
J18.9 [45601123]
J18.9 [45601123]
1.5e+00
—
—
—
—
1.9e+00
4.1e-01
cases:6.47%
controls:1.59%
—
—
—
—
—
—
—
—
cases:4.27%
controls:0.66%
cases:4.14%
controls:2.77%
11
27
159
1670
—
—
—
—
7
11
157
1656
6
43
139
1509
FEV1/FVC
19926-5 [3011505]
19926-5 [3011505]
1.1e+00
—
—
—
—
3.3e+00
—
cases:3.53%
controls:1.18%
—
—
—
—
—
—
—
—
cases:7.32%
controls:0.30%
—
—
6
20
164
1677
—
—
—
—
12
5
152
1662
—
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
19870-5 [3020158]
1.1e+00
—
—
—
—
3.3e+00
—
cases:3.53%
controls:1.18%
—
—
—
—
—
—
—
—
cases:7.32%
controls:0.30%
—
—
6
20
164
1677
—
—
—
—
12
5
152
1662
—
FEV1
20150-9 [3024653]
20150-9 [3024653]
1.1e+00
—
—
—
—
3.3e+00
—
cases:3.53%
controls:1.18%
—
—
—
—
—
—
—
—
cases:7.32%
controls:0.30%
—
—
6
20
164
1677
—
—
—
—
12
5
152
1662
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
62238-1 [40764999]
-1.1e-01
4.1e-01
1.6e+00
—
1.6e+00
7.0e-01
4.3e-01
cases:11.76%
controls:12.91%
cases:14.71%
controls:10.31%
cases:11.18%
controls:2.47%
—
—
cases:9.47%
controls:2.13%
cases:18.90%
controls:10.38%
cases:33.10%
controls:24.36%
20
219
150
1478
25
175
145
1522
19
42
151
1655
—
16
36
153
1655
31
173
133
1494
48
378
97
1174
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
25428-4 [3009261]
5.5e-01
9.8e-01
3.1e+00
—
1.4e+00
9.6e-01
7.3e-01
cases:8.82%
controls:5.30%
cases:7.65%
controls:3.01%
cases:6.47%
controls:0.29%
—
—
cases:2.96%
controls:0.77%
cases:9.76%
controls:3.96%
cases:21.38%
controls:11.60%
15
90
155
1607
13
51
157
1646
11
5
159
1692
—
5
13
164
1678
16
66
148
1601
31
180
114
1372
azathioprine; oral, parenteral
L04AX01 [21603927]
L04AX01 [21603927]
3.1e+00
—
1.0e+50
—
—
—
—
cases:8.24%
controls:0.41%
—
—
cases:4.12%
controls:0.00%
—
—
—
—
—
—
—
—
14
7
156
1690
—
7
0
163
1697
—
—
—
—
risedronic acid; oral
M05BA07 [21604155]
M05BA07 [21604155]
1.9e+00
—
—
—
—
—
3.0e+00
cases:2.94%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:6.21%
controls:0.32%
5
8
165
1689
—
—
—
—
—
9
5
136
1547
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
57782-5 [40760892]
—
7.1e-01
—
—
—
1.6e+00
1.4e+00
—
—
cases:2.94%
controls:1.47%
—
—
—
—
—
—
cases:6.71%
controls:1.50%
cases:11.03%
controls:2.84%
—
5
25
165
1672
—
—
—
11
25
153
1642
16
44
129
1508
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
53027-9 [3041942]
6.3e-01
3.0e+00
—
—
—
—
—
cases:2.94%
controls:1.59%
cases:6.47%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
5
27
165
1670
11
6
159
1691
—
—
—
—
—
FEV1 --post bronchodilation
20155-8 [3023550]
20155-8 [3023550]
1.0e+00
—
—
—
—
2.8e+00
—
cases:2.94%
controls:1.06%
—
—
—
—
—
—
—
—
cases:4.88%
controls:0.30%
—
—
5
18
165
1679
—
—
—
—
8
5
156
1662
—
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
19875-4 [3001668]
1.0e+00
—
—
—
—
2.8e+00
—
cases:2.94%
controls:1.06%
—
—
—
—
—
—
—
—
cases:4.88%
controls:0.30%
—
—
5
18
165
1679
—
—
—
—
8
5
156
1662
—
FEV1/FVC --post bronchodilation
69970-2 [42868459]
69970-2 [42868459]
1.0e+00
—
—
—
—
2.8e+00
—
cases:2.94%
controls:1.06%
—
—
—
—
—
—
—
—
cases:4.88%
controls:0.30%
—
—
5
18
165
1679
—
—
—
—
8
5
156
1662
—
FEV1 percent change
69983-5 [42868472]
69983-5 [42868472]
1.0e+00
—
—
—
—
2.8e+00
—
cases:2.94%
controls:1.06%
—
—
—
—
—
—
—
—
cases:4.88%
controls:0.30%
—
—
5
18
165
1679
—
—
—
—
8
5
156
1662
—
FVC percent change Respiratory system
69982-7 [42868471]
69982-7 [42868471]
1.0e+00
—
—
—
—
2.8e+00
—
cases:2.94%
controls:1.06%
—
—
—
—
—
—
—
—
cases:4.88%
controls:0.30%
—
—
5
18
165
1679
—
—
—
—
8
5
156
1662
—
Extractable nuclear Ab [Units/volume] in Serum
30342-0 [3015171]
30342-0 [3015171]
—
—
1.0e+50
—
—
—
2.8e+00
—
—
—
—
cases:4.71%
controls:0.00%
—
—
—
—
—
—
cases:6.21%
controls:0.39%
—
—
8
0
162
1697
—
—
—
9
6
136
1546
Scheduled procedure
ZXD10 [2001311387]
ZXD10 [2001311387]
9.1e-01
7.1e-01
—
—
—
1.9e+00
1.0e+00
cases:13.53%
controls:5.95%
cases:2.94%
controls:1.47%
—
—
—
—
—
—
cases:4.88%
controls:0.78%
cases:8.97%
controls:3.41%
23
101
147
1596
5
25
165
1672
—
—
—
8
13
156
1654
13
53
132
1499
Biopsy of vaginal cervix
LDA20 [2001306656]
LDA20 [2001306656]
-1.0e+50
—
—
—
—
—
2.7e+00
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:0.32%
0
8
170
1689
—
—
—
—
—
7
5
138
1547
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
TQX10 [2001310152]
1.9e+00
—
—
1.0e+50
—
—
2.7e+00
cases:3.53%
controls:0.53%
—
—
—
—
cases:8.82%
controls:0.00%
—
—
—
—
cases:8.28%
controls:0.58%
6
9
164
1688
—
—
15
0
155
1697
—
—
12
9
133
1543
Ultrasound examination of mammary glands
HA1AE [2001303886]
HA1AE [2001303886]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:0.39%
—
—
—
—
—
—
8
6
137
1546
Arthrocentesis, unspecified region, unspecified region
TNX10 [2001308560]
TNX10 [2001308560]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:0.39%
—
—
—
—
—
—
8
6
137
1546
Extensive body CT
JN4BD [2001310899]
JN4BD [2001310899]
—
—
—
—
—
2.2e+00
2.7e+00
—
—
—
—
—
—
—
—
—
—
cases:3.05%
controls:0.36%
cases:5.52%
controls:0.39%
—
—
—
—
—
5
6
159
1661
8
6
137
1546
Bacterial infection, unspecified
A49.9 [45590816]
A49.9 [45590816]
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
cases:4.27%
controls:0.30%
—
—
—
—
—
—
—
7
5
157
1662
—
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2276-4 [3001122]
6.4e-01
6.6e-01
—
—
2.7e+00
6.2e-01
7.3e-01
cases:8.24%
controls:4.54%
cases:5.88%
controls:3.12%
—
—
—
—
cases:4.14%
controls:0.30%
cases:6.10%
controls:3.36%
cases:17.24%
controls:9.09%
14
77
156
1620
10
53
160
1644
—
—
7
5
162
1686
10
56
154
1611
25
141
120
1411
pH of Urine
2756-5 [3015736]
2756-5 [3015736]
2.0e-01
1.2e+00
2.7e+00
—
1.9e+00
9.2e-01
6.1e-01
cases:5.29%
controls:4.36%
cases:6.47%
controls:2.12%
cases:4.12%
controls:0.29%
—
—
cases:2.96%
controls:0.47%
cases:6.10%
controls:2.52%
cases:15.17%
controls:8.83%
9
74
161
1623
11
36
159
1661
7
5
163
1692
—
5
8
164
1683
10
42
154
1625
22
137
123
1415
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2951-2 [3019550]
2.4e-01
3.5e-01
1.3e+00
—
1.4e+00
4.5e-01
8.0e-02
cases:20.59%
controls:16.97%
cases:18.24%
controls:13.55%
cases:9.41%
controls:2.77%
—
—
cases:9.47%
controls:2.60%
cases:20.12%
controls:13.80%
cases:33.79%
controls:32.02%
35
288
135
1409
31
230
139
1467
16
47
154
1650
—
16
44
153
1647
33
230
131
1437
49
497
96
1055
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2823-3 [3023103]
2.3e-01
3.4e-01
1.3e+00
—
1.4e+00
4.2e-01
6.0e-02
cases:20.59%
controls:17.03%
cases:18.24%
controls:13.67%
cases:9.41%
controls:2.83%
—
—
cases:10.06%
controls:2.72%
cases:20.12%
controls:14.22%
cases:33.79%
controls:32.47%
35
289
135
1408
31
232
139
1465
16
48
154
1649
—
17
46
152
1645
33
237
131
1430
49
504
96
1048
Audiology
64 [38004489]
64 [38004489]
—
2.6e+00
—
—
—
—
5.6e-01
—
—
cases:4.71%
controls:0.35%
—
—
—
—
—
—
—
—
cases:3.45%
controls:2.00%
—
8
6
162
1691
—
—
—
—
5
31
140
1521
Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32730-4 [3043723]
32730-4 [3043723]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.32%
—
—
—
—
—
—
6
5
139
1547
Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32731-2 [3043747]
32731-2 [3043747]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.32%
—
—
—
—
—
—
6
5
139
1547
Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2868-8 [3005229]
2868-8 [3005229]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.32%
—
—
—
—
—
—
6
5
139
1547
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
FB1BD [2001302407]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.32%
—
—
—
—
—
—
6
5
139
1547
Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2874-6 [3023465]
2874-6 [3023465]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.32%
—
—
—
—
—
—
6
5
139
1547
Supplier / Service Provider
OMOP5117446 [33004]
OMOP5117446 [33004]
-1.3e+00
1.1e-01
—
—
—
3.8e+00
—
cases:8.82%
controls:25.63%
cases:9.41%
controls:8.54%
—
—
—
—
—
—
cases:12.20%
controls:0.30%
—
—
15
435
155
1262
16
145
154
1552
—
—
—
20
5
144
1662
—
Telephone, letter or other consultation without direct patient contact
ZY020 [2001311600]
ZY020 [2001311600]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.90%
controls:0.58%
—
—
—
—
—
—
10
9
135
1543
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
11572-5 [3021614]
5.2e-01
2.5e+00
—
—
—
—
—
cases:2.94%
controls:1.77%
cases:7.65%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
5
30
165
1667
13
11
157
1686
—
—
—
—
—
Upper gastrointestinal surgery
106 [44777669]
106 [44777669]
3.4e-01
1.1e+00
—
—
1.7e+00
1.6e+00
9.4e-01
cases:9.41%
controls:6.89%
cases:7.06%
controls:2.36%
—
—
—
—
cases:2.96%
controls:0.53%
cases:7.93%
controls:1.74%
cases:16.55%
controls:7.22%
16
117
154
1580
12
40
158
1657
—
—
5
9
164
1682
13
29
151
1638
24
112
121
1440
Flexible bronchoscopy
UGC12 [2001303610]
UGC12 [2001303610]
2.5e+00
—
—
—
—
—
—
cases:3.53%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
164
1692
—
—
—
—
—
—
denosumab; parenteral
M05BX04 [21604169]
M05BX04 [21604169]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:0.45%
—
—
—
—
—
—
7
7
138
1545
alendronic acid and colecalciferol; oral
M05BB03 [21604160]
M05BB03 [21604160]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.39%
—
—
—
—
—
—
6
6
139
1546
Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection
95941-1 [36031861]
95941-1 [36031861]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.39%
—
—
—
—
—
—
6
6
139
1546
Remowal of suture of skin
TQW40 [2001310146]
TQW40 [2001310146]
-1.0e+50
—
—
—
—
—
2.4e+00
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.39%
0
5
170
1692
—
—
—
—
—
6
6
139
1546
Ribonucleoprotein extractable nuclear Ab [Units/volume] in Serum
29374-6 [3006999]
29374-6 [3006999]
—
1.0e+50
1.0e+50
—
—
—
2.4e+00
—
—
cases:5.29%
controls:0.00%
cases:4.71%
controls:0.00%
—
—
—
—
—
—
cases:3.45%
controls:0.32%
—
9
0
161
1697
8
0
162
1697
—
—
—
5
5
140
1547
oxycodone; oral, parenteral
N02AA05 [21604260]
N02AA05 [21604260]
—
—
—
—
—
2.4e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:4.27%
controls:0.42%
cases:4.83%
controls:0.90%
—
—
—
—
—
7
7
157
1660
7
14
138
1538
Bilateral
ZXA10 [2001311348]
ZXA10 [2001311348]
8.7e-01
—
—
—
—
2.3e+00
—
cases:4.12%
controls:1.77%
—
—
—
—
—
—
—
—
cases:3.05%
controls:0.30%
—
—
7
30
163
1667
—
—
—
—
5
5
159
1662
—
Abnormal findings on diagnostic imaging of lung
R91 [45548995]
R91 [45548995]
2.0e+00
2.3e+00
—
—
—
—
—
cases:2.94%
controls:0.41%
cases:3.53%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
5
7
165
1690
6
6
164
1691
—
—
—
—
—
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
68438-1 [40771025]
8.3e-01
1.2e+00
—
—
—
1.3e+00
1.0e+00
cases:8.24%
controls:3.77%
cases:7.06%
controls:2.30%
—
—
—
—
—
—
cases:9.15%
controls:2.70%
cases:19.31%
controls:7.86%
14
64
156
1633
12
39
158
1658
—
—
—
15
45
149
1622
28
122
117
1430
Gas panel - Venous blood
24339-4 [3000991]
24339-4 [3000991]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:0.58%
—
—
—
—
—
—
8
9
137
1543
DNA double strand Ab [Units/volume] in Serum
5130-0 [3023420]
5130-0 [3023420]
—
1.0e+50
1.0e+50
—
—
—
2.3e+00
—
—
cases:5.88%
controls:0.00%
cases:6.47%
controls:0.00%
—
—
—
—
—
—
cases:5.52%
controls:0.58%
—
10
0
160
1697
11
0
159
1697
—
—
—
8
9
137
1543
Occupational therapy
R4120 [2001310234]
R4120 [2001310234]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.45%
—
—
—
—
—
—
6
7
139
1545
hydroxyzine; oral, parenteral
N05BB01 [21604590]
N05BB01 [21604590]
5.9e-01
2.2e+00
—
—
—
—
7.8e-01
cases:2.94%
controls:1.65%
cases:5.29%
controls:0.59%
—
—
—
—
—
—
—
—
cases:3.45%
controls:1.61%
5
28
165
1669
9
10
161
1687
—
—
—
—
5
25
140
1527
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
D01AE20 [21601959]
—
2.2e+00
—
—
—
—
7.5e-01
—
—
cases:4.12%
controls:0.47%
—
—
—
—
—
—
—
—
cases:4.14%
controls:2.00%
—
7
8
163
1689
—
—
—
—
6
31
139
1521
chlorhexidine
S02AA09 [21605155]
S02AA09 [21605155]
—
2.2e+00
—
—
—
—
7.5e-01
—
—
cases:4.12%
controls:0.47%
—
—
—
—
—
—
—
—
cases:4.14%
controls:2.00%
—
7
8
163
1689
—
—
—
—
6
31
139
1521
chlorhexidine, combinations
D08AC52 [21602208]
D08AC52 [21602208]
—
2.2e+00
—
—
—
—
7.5e-01
—
—
cases:4.12%
controls:0.47%
—
—
—
—
—
—
—
—
cases:4.14%
controls:2.00%
—
7
8
163
1689
—
—
—
—
6
31
139
1521
chlorhexidine
S03AA04 [21605193]
S03AA04 [21605193]
—
2.2e+00
—
—
—
—
7.5e-01
—
—
cases:4.12%
controls:0.47%
—
—
—
—
—
—
—
—
cases:4.14%
controls:2.00%
—
7
8
163
1689
—
—
—
—
6
31
139
1521
hydrocortisone and antiseptics
D07BA04 [21602146]
D07BA04 [21602146]
—
2.2e+00
—
—
—
—
7.5e-01
—
—
cases:4.12%
controls:0.47%
—
—
—
—
—
—
—
—
cases:4.14%
controls:2.00%
—
7
8
163
1689
—
—
—
—
6
31
139
1521
hydrocortisone
D07XA01 [21602180]
D07XA01 [21602180]
—
2.2e+00
—
—
—
—
7.5e-01
—
—
cases:4.12%
controls:0.47%
—
—
—
—
—
—
—
—
cases:4.14%
controls:2.00%
—
7
8
163
1689
—
—
—
—
6
31
139
1521
chlorhexidine
D09AA12 [21602275]
D09AA12 [21602275]
—
2.2e+00
—
—
—
—
7.5e-01
—
—
cases:4.12%
controls:0.47%
—
—
—
—
—
—
—
—
cases:4.14%
controls:2.00%
—
7
8
163
1689
—
—
—
—
6
31
139
1521
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
14631-6 [3006140]
3.8e-01
9.6e-01
—
—
2.2e+00
1.2e+00
5.9e-01
cases:8.24%
controls:5.77%
cases:7.06%
controls:2.83%
—
—
—
—
cases:3.55%
controls:0.41%
cases:6.71%
controls:2.22%
cases:13.10%
controls:7.73%
14
98
156
1599
12
48
158
1649
—
—
6
7
163
1684
11
37
153
1630
19
120
126
1432
High resolution CT examination of lungs
GD1DD [2001303632]
GD1DD [2001303632]
2.2e+00
—
—
—
—
—
—
cases:3.53%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
164
1690
—
—
—
—
—
—
hydrocortisone; local oral
A01AC03 [21600036]
A01AC03 [21600036]
—
2.2e+00
—
—
—
—
—
—
—
cases:3.53%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
6
7
164
1690
—
—
—
—
—
dexamethasone and antiinfectives
S03CA01 [21605206]
S03CA01 [21605206]
1.2e+00
2.2e+00
—
—
—
—
—
cases:4.12%
controls:1.24%
cases:3.53%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
7
21
163
1676
6
7
164
1690
—
—
—
—
—
Kolposcopy
ULA02 [2001306679]
ULA02 [2001306679]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.21%
controls:0.77%
—
—
—
—
—
—
9
12
136
1540
hydrocortisone; oral, parenteral
H02AB09 [21602737]
H02AB09 [21602737]
—
2.1e+00
—
—
—
—
1.1e+00
—
—
cases:4.71%
controls:0.59%
—
—
—
—
—
—
—
—
cases:4.14%
controls:1.35%
—
8
10
162
1687
—
—
—
—
6
21
139
1531
loperamide; oral
A07DA03 [21600646]
A07DA03 [21600646]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.52%
—
—
—
—
—
—
6
8
139
1544
loperamide oxide; oral
A07DA05 [21600648]
A07DA05 [21600648]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.52%
—
—
—
—
—
—
6
8
139
1544
General anesthesia, balanced
WX408 [2001310808]
WX408 [2001310808]
6.4e-01
—
—
—
—
2.1e+00
—
cases:6.47%
controls:3.54%
—
—
—
—
—
—
—
—
cases:4.27%
controls:0.54%
—
—
11
60
159
1637
—
—
—
—
7
9
157
1658
—
Abnormal findings in specimens from female genital organs, abnormal cytological findings
R87.6 [45558487]
R87.6 [45558487]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.90%
controls:0.90%
—
—
—
—
—
—
10
14
135
1538
triamcinolone and antiseptics
D07BB03 [21602150]
D07BB03 [21602150]
—
2.1e+00
—
—
—
—
6.9e-01
—
—
cases:4.12%
controls:0.53%
—
—
—
—
—
—
—
—
cases:4.14%
controls:2.13%
—
7
9
163
1688
—
—
—
—
6
33
139
1519
nystatin; oral
A07AA02 [21600604]
A07AA02 [21600604]
2.1e+00
—
—
—
—
—
—
cases:4.12%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
7
9
163
1688
—
—
—
—
—
—
Medical Oncology
90 [38004507]
90 [38004507]
4.8e-01
1.0e+00
—
—
2.0e+00
1.3e+00
1.0e+00
cases:4.12%
controls:2.59%
cases:5.88%
controls:2.18%
—
—
—
—
cases:3.55%
controls:0.47%
cases:6.10%
controls:1.74%
cases:8.97%
controls:3.48%
7
44
163
1653
10
37
160
1660
—
—
6
8
163
1683
10
29
154
1638
13
54
132
1498
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
J01EE01 [21602961]
2.0e+00
—
1.0e+50
—
—
—
1.0e+50
cases:3.53%
controls:0.47%
—
—
cases:3.53%
controls:0.00%
—
—
—
—
—
—
cases:8.28%
controls:0.00%
6
8
164
1689
—
6
0
164
1697
—
—
—
12
0
133
1552
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
5195-3 [3019284]
1.0e+00
—
—
—
—
2.0e+00
1.2e+00
cases:4.71%
controls:1.77%
—
—
—
—
—
—
—
—
cases:4.88%
controls:0.66%
cases:6.21%
controls:1.93%
8
30
162
1667
—
—
—
—
8
11
156
1656
9
30
136
1522
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
14879-1 [3003458]
9.3e-01
—
—
—
—
2.0e+00
8.2e-01
cases:2.94%
controls:1.18%
—
—
—
—
—
—
—
—
cases:4.88%
controls:0.66%
cases:3.45%
controls:1.55%
5
20
165
1677
—
—
—
—
8
11
156
1656
5
24
140
1528
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
26498-6 [3017181]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.28%
controls:1.16%
—
—
—
—
—
—
12
18
133
1534
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
14675-3 [3036481]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.34%
controls:1.48%
—
—
—
—
—
—
15
23
130
1529
Hypothyroidism, unspecified
E03.9 [45537945]
E03.9 [45537945]
1.2e+00
2.0e+00
—
—
—
—
6.8e-01
cases:4.12%
controls:1.30%
cases:4.71%
controls:0.65%
—
—
—
—
—
—
—
—
cases:4.83%
controls:2.51%
7
22
163
1675
8
11
162
1686
—
—
—
—
7
39
138
1513
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
16933-4 [3021879]
2.0e+00
—
—
—
—
—
—
cases:4.71%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
8
11
162
1686
—
—
—
—
—
—
terbinafine; oral
D01BA02 [21601967]
D01BA02 [21601967]
—
2.0e+00
—
—
—
—
6.5e-01
—
—
cases:4.71%
controls:0.65%
—
—
—
—
—
—
—
—
cases:5.52%
controls:2.96%
—
8
11
162
1686
—
—
—
—
8
46
137
1506
Sytologyspecimen from mouth of uterus
XLD00 [2001306651]
XLD00 [2001306651]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:0.77%
—
—
—
—
—
—
8
12
137
1540
Disease/condition unspecnature/site
A99 [2002000232]
A99 [2002000232]
—
-1.0e+50
—
—
—
—
2.0e+00
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
cases:5.52%
controls:0.77%
—
0
5
170
1692
—
—
—
—
8
12
137
1540
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
NA3AA [2001307026]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:0.58%
—
—
—
—
—
—
6
9
139
1543
Infectious Disease
44 [38004484]
44 [38004484]
1.6e+00
2.1e+00
—
—
—
2.0e+00
1.4e+00
cases:4.71%
controls:1.00%
cases:2.94%
controls:0.35%
—
—
—
—
—
—
cases:4.27%
controls:0.60%
cases:5.52%
controls:1.35%
8
17
162
1680
5
6
165
1691
—
—
—
7
10
157
1657
8
21
137
1531
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
14804-9 [3022250]
—
2.0e+00
1.0e+50
—
—
—
2.0e+00
—
—
cases:2.94%
controls:0.41%
cases:2.94%
controls:0.00%
—
—
—
—
—
—
cases:8.97%
controls:1.35%
—
5
7
165
1690
5
0
165
1697
—
—
—
13
21
132
1531
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
LC2BE [2001306544]
1.1e+00
—
—
—
—
2.0e+00
4.6e-01
cases:7.65%
controls:2.77%
—
—
—
—
—
—
—
—
cases:6.10%
controls:0.90%
cases:5.52%
controls:3.54%
13
47
157
1650
—
—
—
—
10
15
154
1652
8
55
137
1497
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
24351-9 [3004588]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:0.71%
—
—
—
—
—
—
7
11
138
1541
tacrolimus
D11AH01 [21602338]
D11AH01 [21602338]
—
2.3e+00
—
—
—
—
2.0e+00
—
—
cases:2.94%
controls:0.29%
—
—
—
—
—
—
—
—
cases:4.83%
controls:0.71%
—
5
5
165
1692
—
—
—
—
7
11
138
1541
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
26524-9 [3021440]
-1.0e+50
—
—
—
—
—
1.9e+00
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
cases:7.59%
controls:1.16%
0
7
170
1690
—
—
—
—
—
11
18
134
1534
Intravenous general anesthesia
WX404 [2001310807]
WX404 [2001310807]
6.4e-01
—
—
—
—
—
1.9e+00
cases:4.71%
controls:2.53%
—
—
—
—
—
—
—
—
—
—
cases:5.52%
controls:0.84%
8
43
162
1654
—
—
—
—
—
8
13
137
1539
clobetasol
D07AD01 [21602141]
D07AD01 [21602141]
1.1e+00
1.2e+00
—
—
—
1.9e+00
1.1e+00
cases:4.12%
controls:1.36%
cases:2.94%
controls:0.88%
—
—
—
—
—
—
cases:5.49%
controls:0.84%
cases:6.90%
controls:2.51%
7
23
163
1674
5
15
165
1682
—
—
—
9
14
155
1653
10
39
135
1513
Pain in joint
M25.5 [45586941]
M25.5 [45586941]
8.8e-01
1.9e+00
—
—
—
—
4.7e-01
cases:7.06%
controls:3.06%
cases:6.47%
controls:1.00%
—
—
—
—
—
—
—
—
cases:7.59%
controls:4.90%
12
52
158
1645
11
17
159
1680
—
—
—
—
11
76
134
1476
Blasts/Leukocytes in Blood
26446-5 [3025159]
26446-5 [3025159]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.90%
controls:1.10%
—
—
—
—
—
—
10
17
135
1535
Emergency Medicine
93 [38004510]
93 [38004510]
6.2e-02
4.8e-01
1.9e+00
—
1.7e+00
8.5e-01
3.9e-01
cases:8.24%
controls:7.78%
cases:7.65%
controls:4.89%
cases:4.12%
controls:0.65%
—
—
cases:3.55%
controls:0.65%
cases:8.54%
controls:3.84%
cases:19.31%
controls:13.98%
14
132
156
1565
13
83
157
1614
7
11
163
1686
—
6
11
163
1680
14
64
150
1603
28
217
117
1335
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
75622-1 [46235355]
2.1e-01
1.2e+00
—
—
—
1.9e+00
1.2e+00
cases:4.12%
controls:3.36%
cases:2.94%
controls:0.94%
—
—
—
—
—
—
cases:4.88%
controls:0.78%
cases:7.59%
controls:2.32%
7
57
163
1640
5
16
165
1681
—
—
—
8
13
156
1654
11
36
134
1516
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
51485-1 [3030306]
1.2e+00
1.9e+00
—
—
—
1.6e+00
6.7e-01
cases:4.12%
controls:1.24%
cases:4.71%
controls:0.77%
—
—
—
—
—
—
cases:3.05%
controls:0.66%
cases:5.52%
controls:2.90%
7
21
163
1676
8
13
162
1684
—
—
—
5
11
159
1656
8
45
137
1507
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
28541-1 [3002179]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.90%
controls:1.16%
—
—
—
—
—
—
10
18
135
1534
Dentistry
C5 [903277]
C5 [903277]
8.0e-01
—
—
—
—
1.8e+00
7.2e-01
cases:4.12%
controls:1.89%
—
—
—
—
—
—
—
—
cases:4.27%
controls:0.72%
cases:4.14%
controls:2.06%
7
32
163
1665
—
—
—
—
7
12
157
1655
6
32
139
1520
zopiclone; oral
N05CF01 [21604654]
N05CF01 [21604654]
7.9e-01
5.1e-01
—
—
1.8e+00
7.8e-01
5.7e-01
cases:14.12%
controls:6.95%
cases:8.24%
controls:5.13%
—
—
—
—
cases:6.51%
controls:1.12%
cases:9.76%
controls:4.74%
cases:13.10%
controls:7.86%
24
118
146
1579
14
87
156
1610
—
—
11
19
158
1672
16
79
148
1588
19
122
126
1430
Coloscopy
UJF32 [2001305029]
UJF32 [2001305029]
1.0e+00
—
—
—
—
1.8e+00
3.7e-01
cases:8.24%
controls:3.12%
—
—
—
—
—
—
—
—
cases:4.88%
controls:0.84%
cases:6.21%
controls:4.38%
14
53
156
1644
—
—
—
—
8
14
156
1653
9
68
136
1484
Other seropositive rheumatoid arthritis
M05.8 [45538634]
M05.8 [45538634]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:0.84%
—
—
—
—
—
—
7
13
138
1539
Bacteria identified in Blood by Culture
600-7 [3023368]
600-7 [3023368]
4.4e-01
1.2e+00
—
—
—
1.8e+00
1.0e+00
cases:3.53%
controls:2.30%
cases:4.12%
controls:1.24%
—
—
—
—
—
—
cases:5.49%
controls:0.96%
cases:7.59%
controls:2.84%
6
39
164
1658
7
21
163
1676
—
—
—
9
16
155
1651
11
44
134
1508
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
40982-1 [3038288]
1.4e+00
—
—
—
—
—
1.8e+00
cases:2.94%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:6.21%
controls:1.10%
5
12
165
1685
—
—
—
—
—
9
17
136
1535
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
51486-9 [3029879]
1.0e+00
1.7e+00
—
—
—
—
4.6e-01
cases:4.12%
controls:1.53%
cases:4.71%
controls:0.88%
—
—
—
—
—
—
—
—
cases:4.14%
controls:2.64%
7
26
163
1671
8
15
162
1682
—
—
—
—
6
41
139
1511
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
D01AC20 [21601936]
3.9e-01
1.7e+00
—
—
—
—
3.1e-01
cases:4.71%
controls:3.24%
cases:5.29%
controls:1.00%
—
—
—
—
—
—
—
—
cases:5.52%
controls:4.12%
8
55
162
1642
9
17
161
1680
—
—
—
—
8
64
137
1488
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
34487-9 [3044938]
1.1e+00
—
—
—
—
—
1.7e+00
cases:2.94%
controls:1.00%
—
—
—
—
—
—
—
—
—
—
cases:7.59%
controls:1.55%
5
17
165
1680
—
—
—
—
—
11
24
134
1528
sulfadiazine and trimethoprim
J01EE02 [21602962]
J01EE02 [21602962]
8.8e-02
—
—
—
—
—
1.6e+00
cases:3.53%
controls:3.24%
—
—
—
—
—
—
—
—
—
—
cases:9.66%
controls:2.06%
6
55
164
1642
—
—
—
—
—
14
32
131
1520
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
40987-0 [3043924]
1.4e+00
—
—
—
—
—
1.6e+00
cases:2.94%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:6.21%
controls:1.29%
5
12
165
1685
—
—
—
—
—
9
20
136
1532
folic acid
V04CX02 [715877]
V04CX02 [715877]
—
-1.0e+50
—
—
—
2.0e+00
1.6e+00
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:3.05%
controls:0.42%
cases:7.59%
controls:1.61%
—
0
5
170
1692
—
—
—
5
7
159
1660
11
25
134
1527
folic acid; oral, parenteral
B03BB01 [21601129]
B03BB01 [21601129]
—
-1.0e+50
—
—
—
2.0e+00
1.6e+00
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:3.05%
controls:0.42%
cases:7.59%
controls:1.61%
—
0
5
170
1692
—
—
—
5
7
159
1660
11
25
134
1527
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
51483-6 [3030467]
7.8e-01
1.6e+00
—
—
2.3e+00
1.3e+00
8.1e-01
cases:6.47%
controls:3.06%
cases:6.47%
controls:1.41%
—
—
—
—
cases:2.96%
controls:0.30%
cases:6.10%
controls:1.68%
cases:10.34%
controls:4.90%
11
52
159
1645
11
24
159
1673
—
—
5
5
164
1686
10
28
154
1639
15
76
130
1476
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
51480-2 [3031040]
3.5e-01
8.4e-01
1.5e+00
—
1.5e+00
4.1e-01
4.5e-01
cases:11.76%
controls:8.60%
cases:10.00%
controls:4.60%
cases:3.53%
controls:0.82%
—
—
cases:5.33%
controls:1.18%
cases:7.93%
controls:5.40%
cases:20.69%
controls:14.30%
20
146
150
1551
17
78
153
1619
6
14
164
1683
—
9
20
160
1671
13
90
151
1577
30
222
115
1330
desloratadine; oral
R06AX27 [21603526]
R06AX27 [21603526]
—
1.5e+00
—
—
—
—
2.0e-02
—
—
cases:8.24%
controls:1.89%
—
—
—
—
—
—
—
—
cases:5.52%
controls:5.41%
—
14
32
156
1665
—
—
—
—
8
84
137
1468
Bacteria [Presence] in Urine
87829-8 [36304419]
87829-8 [36304419]
7.6e-01
1.5e+00
—
—
2.3e+00
1.3e+00
9.1e-01
cases:6.47%
controls:3.12%
cases:6.47%
controls:1.47%
—
—
—
—
cases:2.96%
controls:0.30%
cases:6.10%
controls:1.68%
cases:10.34%
controls:4.45%
11
53
159
1644
11
25
159
1672
—
—
5
5
164
1686
10
28
154
1639
15
69
130
1483
General Surgery
2 [38004447]
2 [38004447]
5.1e-01
5.7e-01
—
—
1.7e+00
1.5e+00
6.1e-01
cases:27.65%
controls:18.74%
cases:9.41%
controls:5.54%
—
—
—
—
cases:2.96%
controls:0.53%
cases:17.68%
controls:4.50%
cases:23.45%
controls:14.24%
47
318
123
1379
16
94
154
1603
—
—
5
9
164
1682
29
75
135
1592
34
221
111
1331
Laceration/cut
S18 [2002000983]
S18 [2002000983]
3.6e-01
3.9e-01
—
—
—
1.4e+00
6.4e-02
cases:5.88%
controls:4.18%
cases:2.94%
controls:2.00%
—
—
—
—
—
—
cases:7.32%
controls:1.92%
cases:7.59%
controls:7.15%
10
71
160
1626
5
34
165
1663
—
—
—
12
32
152
1635
11
111
134
1441
Limited function/disability (L)
L28 [2002000647]
L28 [2002000647]
1.2e+00
2.1e+00
—
—
—
—
1.3e+00
cases:3.53%
controls:1.12%
cases:2.94%
controls:0.35%
—
—
—
—
—
—
—
—
cases:8.28%
controls:2.32%
6
19
164
1678
5
6
165
1691
—
—
—
—
12
36
133
1516
Plastic And Reconstructive Surgery
24 [38004467]
24 [38004467]
—
—
—
—
—
1.6e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:3.66%
controls:0.78%
cases:8.28%
controls:2.38%
—
—
—
—
—
6
13
158
1654
12
37
133
1515
Urgent procedure
ZXD05 [2001311386]
ZXD05 [2001311386]
4.0e-01
—
—
—
—
—
1.2e+00
cases:6.47%
controls:4.42%
—
—
—
—
—
—
—
—
—
—
cases:8.97%
controls:2.77%
11
75
159
1622
—
—
—
—
—
13
43
132
1509
Telephone prescription or other care instructions
WZB00 [2001310884]
WZB00 [2001310884]
-1.9e-02
—
—
—
—
—
1.2e+00
cases:3.53%
controls:3.59%
—
—
—
—
—
—
—
—
—
—
cases:11.72%
controls:3.74%
6
61
164
1636
—
—
—
—
—
17
58
128
1494
Dyspnoea
R06.0 [45558449]
R06.0 [45558449]
8.8e-01
1.7e+00
—
—
—
—
1.2e+00
cases:4.71%
controls:2.00%
cases:4.12%
controls:0.77%
—
—
—
—
—
—
—
—
cases:10.34%
controls:3.29%
8
34
162
1663
7
13
163
1684
—
—
—
—
15
51
130
1501
cetirizine; oral
R06AE07 [21603497]
R06AE07 [21603497]
3.4e-01
1.2e+00
—
—
-1.0e+50
9.4e-01
5.4e-01
cases:11.18%
controls:8.19%
cases:10.00%
controls:3.18%
—
—
—
—
cases:0.00%
controls:0.65%
cases:7.32%
controls:3.00%
cases:13.10%
controls:8.05%
19
139
151
1558
17
54
153
1643
—
—
0
11
169
1680
12
50
152
1617
19
125
126
1427
Otolaryngology
4 [38004449]
4 [38004449]
3.5e-01
1.2e+00
1.6e+00
—
—
7.1e-01
6.0e-01
cases:13.53%
controls:9.90%
cases:10.00%
controls:3.24%
cases:2.94%
controls:0.59%
—
—
—
—
cases:6.71%
controls:3.42%
cases:15.86%
controls:9.34%
23
168
147
1529
17
55
153
1642
5
10
165
1687
—
—
11
57
153
1610
23
145
122
1407
Psychiatry
26 [38004469]
26 [38004469]
5.8e-02
2.8e-01
—
—
—
7.9e-01
1.2e+00
cases:5.29%
controls:5.01%
cases:2.94%
controls:2.24%
—
—
—
—
—
—
cases:4.88%
controls:2.28%
cases:15.17%
controls:5.28%
9
85
161
1612
5
38
165
1659
—
—
—
8
38
156
1629
22
82
123
1470
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
33762-6 [3029187]
8.4e-01
1.1e+00
—
—
—
1.4e+00
1.2e+00
cases:4.12%
controls:1.83%
cases:2.94%
controls:1.00%
—
—
—
—
—
—
cases:3.05%
controls:0.78%
cases:13.10%
controls:4.51%
7
31
163
1666
5
17
165
1680
—
—
—
5
13
159
1654
19
70
126
1482
One hour or less
ZXE00 [2001311394]
ZXE00 [2001311394]
5.4e-01
7.5e-01
—
—
—
1.6e+00
1.2e+00
cases:9.41%
controls:5.72%
cases:2.94%
controls:1.41%
—
—
—
—
—
—
cases:4.27%
controls:0.90%
cases:11.72%
controls:3.99%
16
97
154
1600
5
24
165
1673
—
—
—
7
15
157
1652
17
62
128
1490
Low back pain
M54.5 [45553207]
M54.5 [45553207]
1.6e-02
—
-1.0e+50
—
-1.0e+50
—
1.1e+00
cases:3.53%
controls:3.48%
—
—
cases:0.00%
controls:0.29%
—
—
cases:0.00%
controls:0.41%
—
—
cases:12.41%
controls:4.38%
6
59
164
1638
—
0
5
170
1692
—
0
7
169
1684
—
18
68
127
1484
codeine and paracetamol
N02AJ06 [1123647]
N02AJ06 [1123647]
5.2e-01
-1.3e-01
—
—
-1.0e+50
1.3e-01
7.6e-01
cases:15.29%
controls:9.72%
cases:4.12%
controls:4.66%
—
—
—
—
cases:0.00%
controls:0.71%
cases:4.27%
controls:3.78%
cases:24.14%
controls:12.95%
26
165
144
1532
7
79
163
1618
—
—
0
12
169
1679
7
63
157
1604
35
201
110
1351
Orthopedic Surgery
20 [38004465]
20 [38004465]
5.5e-01
1.5e-01
—
—
—
6.0e-01
7.2e-01
cases:17.65%
controls:10.96%
cases:4.71%
controls:4.07%
—
—
—
—
—
—
cases:7.93%
controls:4.50%
cases:26.21%
controls:14.76%
30
186
140
1511
8
69
162
1628
—
—
—
13
75
151
1592
38
229
107
1323
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
N02BE01 [21604344]
2.0e-02
2.6e-01
4.9e-01
—
6.7e-01
6.6e-01
6.6e-01
cases:24.12%
controls:23.75%
cases:16.47%
controls:13.20%
cases:2.94%
controls:1.83%
—
—
cases:4.73%
controls:2.48%
cases:21.95%
controls:12.66%
cases:50.34%
controls:34.41%
41
403
129
1294
28
224
142
1473
5
31
165
1666
—
8
42
161
1649
36
211
128
1456
73
534
72
1018
Phlebitis and thrombophlebitis of other deep vessels of lower extremities
I80.29 [2000502545]
I80.29 [2000502545]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
0
5
145
1547
Gynecological ultrasound examination as part of clinical examination
LX1AE [2001306815]
LX1AE [2001306815]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
0
11
170
1686
—
—
—
—
—
Hyperlipidaemia, unspecified
E78.5 [45537986]
E78.5 [45537986]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
0
8
170
1689
—
—
—
—
—
chloramphenicol
D10AF03 [21602307]
D10AF03 [21602307]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:0.00%
controls:0.90%
—
—
—
—
—
0
5
164
1662
0
14
145
1538
Other specified pulpit
K04.08 [2000502703]
K04.08 [2000502703]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
170
1690
—
—
—
—
—
—
nitrazepam; oral
N05CD02 [21604637]
N05CD02 [21604637]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
170
1691
—
—
—
—
—
—
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
620-5 [3007853]
7.1e-01
—
—
—
—
—
1.4e+00
cases:2.94%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:1.29%
5
25
165
1672
—
—
—
—
—
7
20
138
1532
Hyperemia of pulp
K04.00 [2000502702]
K04.00 [2000502702]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
170
1690
—
—
—
—
—
—
Gas panel - Capillary blood
24337-8 [3022313]
24337-8 [3022313]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
170
1692
—
—
—
—
—
—
Benign neoplasm: Transverse colon
D12.3 [45581282]
D12.3 [45581282]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
170
1692
—
—
—
—
—
—
Migraine, unspecified
G43.9 [45595943]
G43.9 [45595943]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
0
8
170
1689
—
—
—
—
0
5
164
1662
—
Stomatognathic treatment, simple
SHA01 [2001310405]
SHA01 [2001310405]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
20
170
1677
—
—
—
—
—
—
Left sided colitis
K51.5 [45533604]
K51.5 [45533604]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
145
1546
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
94500-6 [706163]
-9.0e-02
7.0e-02
—
—
—
—
1.8e-01
cases:4.71%
controls:5.13%
cases:3.53%
controls:3.30%
—
—
—
—
—
—
—
—
cases:14.48%
controls:12.44%
8
87
162
1610
6
56
164
1641
—
—
—
—
21
193
124
1359
Back symptom/complaint
L02 [2002000627]
L02 [2002000627]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
170
1683
—
—
—
—
—
—
Thyrotoxicosis with diffuse goitre
E05.0 [45600628]
E05.0 [45600628]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
0
5
170
1692
—
—
—
—
—
zolpidem; oral
N05CF02 [21604655]
N05CF02 [21604655]
—
—
—
—
—
—
2.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.14%
controls:3.41%
—
—
—
—
—
—
6
53
139
1499
fluocortolone
D07AC05 [21602124]
D07AC05 [21602124]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
0
12
170
1685
0
6
170
1691
—
—
—
—
0
11
145
1541
Sleep disturbance
P06 [2002000803]
P06 [2002000803]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.83%
controls:0.97%
—
—
—
—
—
—
7
15
138
1537
Streptococcus pyogenes Ag [Presence] in Throat
18481-2 [3033319]
18481-2 [3033319]
-1.0e+50
—
—
—
—
—
8.6e-01
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:1.48%
0
19
170
1678
—
—
—
—
—
5
23
140
1529
Procedure duration 90 to 119 minutes
ZXE13 [2001311404]
ZXE13 [2001311404]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
170
1692
—
—
—
—
—
—
Laparoscopic hysterectomy
LCD04 [2001306586]
LCD04 [2001306586]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
145
1546
Impacted cerumen
H61.2 [45562307]
H61.2 [45562307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
170
1692
—
—
—
—
—
—
Opiates [Presence] in Urine
3879-4 [3027008]
3879-4 [3027008]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.65%
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:0.00%
controls:0.48%
cases:0.00%
controls:0.71%
0
11
170
1686
0
5
170
1692
—
—
—
0
8
164
1659
0
11
145
1541
levonorgestrel
G03AC03 [21602499]
G03AC03 [21602499]
—
-1.0e+50
—
—
—
-1.0e+50
5.9e-01
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
cases:0.00%
controls:0.30%
cases:3.45%
controls:1.93%
—
0
7
170
1690
—
—
—
0
5
164
1662
5
30
140
1522
Knee symptom/complaint
L15 [2002000639]
L15 [2002000639]
1.0e+00
-1.0e+50
—
—
—
—
—
cases:4.71%
controls:1.77%
cases:0.00%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
8
30
162
1667
0
13
170
1684
—
—
—
—
—
Two-surface restoration
SFA20 [2001310359]
SFA20 [2001310359]
-7.7e-03
-8.8e-02
—
—
—
2.7e-01
1.4e-01
cases:11.76%
controls:11.84%
cases:4.12%
controls:4.48%
—
—
—
—
—
—
cases:6.71%
controls:5.22%
cases:17.24%
controls:15.27%
20
201
150
1496
7
76
163
1621
—
—
—
11
87
153
1580
25
237
120
1315
Localized swelling, mass and lump, neck
R22.1 [45592412]
R22.1 [45592412]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
0
5
170
1692
—
—
—
—
—
0
6
145
1546
CT angiography of head and neck vasculature
PA7AD [2001300233]
PA7AD [2001300233]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
0
5
170
1692
—
—
—
—
—
0
6
145
1546
Laser discission of secondary cataract
CJB10 [2001301313]
CJB10 [2001301313]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.36%
—
—
—
—
—
—
—
0
6
164
1661
—
Presence of intraocular lens
Z96.1 [45585885]
Z96.1 [45585885]
—
-1.0e+50
—
—
—
—
8.2e-01
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
cases:4.14%
controls:1.87%
—
0
9
170
1688
—
—
—
—
6
29
139
1523
Ventricular premature depolarization
I49.3 [45538386]
I49.3 [45538386]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
0
5
170
1692
—
—
—
0
7
164
1660
—
Loss of teeth due to accident, extraction or local periodontal disease
K08.1 [45591573]
K08.1 [45591573]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
0
7
170
1690
—
—
—
—
—
Biopsy of muscle
NXL00 [2001308515]
NXL00 [2001308515]
—
1.0e+50
—
—
—
—
—
—
—
cases:3.53%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
6
0
164
1697
—
—
—
—
—
Angina pectoris, unspecified
I20.90 [2000502402]
I20.90 [2000502402]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
170
1691
—
—
—
—
—
—
Asthma
R96 [2002000961]
R96 [2002000961]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
—
0
7
164
1660
—
Back syndrome with radiating pain
L86 [2002000705]
L86 [2002000705]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
170
1691
—
—
—
—
—
—
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
R01BA51 [21603212]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
0
8
164
1659
—
Person consulting for explanation of investigation findings
Z71.2 [45552100]
Z71.2 [45552100]
—
—
—
—
—
-1.0e+50
1.8e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
cases:4.83%
controls:4.06%
—
—
—
—
—
0
17
164
1650
7
63
138
1489
sildenafil; oral
G04BE03 [21602648]
G04BE03 [21602648]
—
-1.0e+50
—
—
—
—
4.4e-01
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
—
cases:3.45%
controls:2.26%
—
0
17
170
1680
—
—
—
—
5
35
140
1517
Paranoid schizophrenia continuous
F20.00 [2000501920]
F20.00 [2000501920]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
0
5
170
1692
—
—
—
—
—
0
6
145
1546
metformin; oral
A10BA02 [21600747]
A10BA02 [21600747]
-4.5e-01
-7.9e-01
—
—
—
-3.4e-01
-1.5e-02
cases:4.12%
controls:6.31%
cases:2.94%
controls:6.25%
—
—
—
—
—
—
cases:4.88%
controls:6.72%
cases:8.97%
controls:9.09%
7
107
163
1590
5
106
165
1591
—
—
—
8
112
156
1555
13
141
132
1411
Caries limited to enamel
K02.0 [45576967]
K02.0 [45576967]
—
—
—
—
—
—
-9.3e-03
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:3.48%
—
—
—
—
—
—
5
54
140
1498
buspirone; oral
N05BE01 [21604601]
N05BE01 [21604601]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
0
6
170
1691
0
6
170
1691
—
—
—
—
—
Neurosurgery
14 [38004459]
14 [38004459]
8.2e-01
-1.0e+50
—
—
—
—
—
cases:3.53%
controls:1.59%
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
6
27
164
1670
0
8
170
1689
—
—
—
—
—
Rectal ultrasound examination of prostate
KE1BE [2001306106]
KE1BE [2001306106]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
0
8
170
1689
—
—
—
—
0
5
164
1662
—
Acute bronchitis, unspecified
J20.9 [45562445]
J20.9 [45562445]
7.1e-01
—
—
—
—
—
—
cases:3.53%
controls:1.77%
—
—
—
—
—
—
—
—
—
—
—
—
6
30
164
1667
—
—
—
—
—
—
Pregnancy, not (yet) confirmed
Z32.0 [45585821]
Z32.0 [45585821]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
170
1692
—
—
—
—
—
—
Microalbumin [Mass/volume] in Urine
14957-5 [3000034]
14957-5 [3000034]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
145
1546
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
Z00.4 [45605094]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.45%
controls:0.71%
—
—
—
—
—
—
5
11
140
1541
finasteride; oral
D11AX10 [21602350]
D11AX10 [21602350]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
0
6
169
1685
—
—
Benign neoplasm: Sigmoid colon
D12.5 [45552326]
D12.5 [45552326]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
170
1690
—
—
—
—
—
—
Monitoring of emergency patient
SPAT1104 [2001700205]
SPAT1104 [2001700205]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
170
1689
—
—
—
—
—
—
venlafaxine; oral
N06AX16 [21604745]
N06AX16 [21604745]
3.9e-01
—
-1.0e+50
—
—
1.4e+00
6.6e-01
cases:2.94%
controls:2.00%
—
—
cases:0.00%
controls:0.29%
—
—
—
—
cases:4.27%
controls:1.14%
cases:3.45%
controls:1.80%
5
34
165
1663
—
0
5
170
1692
—
—
7
19
157
1648
5
28
140
1524
Redundant prepuce, phimosis and paraphimosis
N47 [45596870]
N47 [45596870]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
170
1691
—
—
—
—
—
—
Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection
92695-6 [37019628]
92695-6 [37019628]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
6
145
1546
Acute subendocardial infarction stenosed coronary artery
I21.41 [2000502433]
I21.41 [2000502433]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
170
1691
—
—
—
—
—
—
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
1805-1 [3016417]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
0
8
164
1659
—
formoterol; inhalant
R03AC13 [21603267]
R03AC13 [21603267]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
170
1692
—
—
—
—
—
—
Removal of sutures from oral mucosa
SXB00 [2001310580]
SXB00 [2001310580]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
170
1689
—
—
—
—
—
—
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
A03FA01 [21600484]
6.3e-01
1.3e+00
—
—
—
1.5e+00
3.7e-02
cases:5.29%
controls:2.89%
cases:2.94%
controls:0.82%
—
—
—
—
—
—
cases:4.27%
controls:0.96%
cases:4.14%
controls:3.99%
9
49
161
1648
5
14
165
1683
—
—
—
7
16
157
1651
6
62
139
1490
Bloodpressure measurement
XF600 [2001303376]
XF600 [2001303376]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
—
—
0
12
170
1685
0
6
170
1691
—
—
—
—
—
Ova and parasites identified in Stool by Light microscopy
10704-5 [3003327]
10704-5 [3003327]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
11
145
1541
LabWAS
↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
77
33
39.40
113.16
1.8
1.2
87.00
—
u/ml
—
5
0
52
6
119.65
49.91
1.3
1.0
—
—
—
0
0
54
61
12.11
46.14
2.1
1.4
2.49
3.22
iu/ml
0.22
14
11
46
46
13.00
42.50
1.6
1.1
0.20
0.25
g/l
2.85
46
46
46
48
12.44
41.26
1.6
1.1
1.13
1.25
g/l
1.28
46
48
40
40
12.50
36.72
1.5
1.2
3.58
2.20
u/ml
—
5
5
149
891
4.53
16.15
22.5
10.3
4.07
4.11
e9/l
0.08
143
778
20
6
37.11
16.10
1.3
1.0
—
—
—
0
0
21
13
18.04
13.83
1.3
1.0
—
—
—
0
0
20
12
18.51
13.32
1.3
1.0
—
—
—
0
0
20
12
18.51
13.32
1.3
1.1
—
—
—
0
0
20
13
17.08
12.95
1.3
1.0
—
—
—
0
0
20
13
17.08
12.95
1.3
1.0
—
—
—
0
0
20
14
15.86
12.60
1.3
1.0
—
—
—
0
0
24
51
5.26
11.07
1.4
2.8
0.00
0.00
g/l
-0.00
24
46
21
40
5.80
10.87
1.2
1.4
550.10
0.14
iu/ml
—
6
5
21
41
5.65
10.59
3.8
2.6
—
—
—
0
0
123
799
2.63
8.72
10.7
7.1
1.21
1.21
mmol/l
0.19
113
683
19
45
4.59
7.68
2.8
3.0
4.43
1.57
index
—
7
28
82
462
2.40
7.64
4.6
3.0
0.17
0.52
e6/l
1.97
62
329
33
118
3.19
7.48
1.3
3.4
63.92
66.33
g/l
0.91
33
110
20
51
4.28
7.38
1.1
1.2
—
—
—
0
0
17
43
4.25
6.32
1.8
1.6
—
—
—
0
0
122
857
2.26
6.31
6.3
3.8
0.00
0.00
estimate
-0.00
23
197
124
877
2.27
6.30
6.3
3.8
0.00
0.00
estimate
-0.00
22
191
122
863
2.23
6.11
6.3
3.8
0.00
8.00
estimate
0.50
23
203
16
41
4.18
5.85
1.9
1.6
—
—
—
0
0
50
253
2.34
5.71
2.4
1.8
—
—
—
0
0
10
10
10.49
5.60
2.4
1.3
—
—
—
0
0
38
174
2.49
5.38
2.3
1.8
—
—
—
0
0
52
275
2.24
5.32
3.7
2.8
0.55
0.79
e6/l
0.66
32
139
38
176
2.46
5.24
10.7
8.0
11.12
12.47
kpa
0.90
32
170
38
176
2.46
5.24
10.7
8.0
5.49
5.05
kpa
1.40
32
170
15
35
4.57
4.75
2.0
1.4
—
—
—
0
0
36
170
2.39
4.75
11.1
8.3
2.72
0.75
mmol/l
1.15
29
139
11
18
6.42
4.68
1.9
1.3
—
—
—
0
0
8
9
9.23
4.32
2.6
2.4
—
—
—
0
0
46
254
2.08
4.14
4.2
3.0
3.45
2.75
e6/l
0.21
26
121
52
307
1.97
3.87
4.5
4.0
205.80
258.77
ng/l
0.16
46
238
71
465
1.86
3.87
4.4
3.5
1062.65
1389.58
ng/l
0.54
64
400
11
24
4.80
3.81
1.2
1.4
121.76
160.33
au/ml
—
5
6
12
32
3.94
3.46
2.3
1.4
—
—
—
0
0
11
27
4.26
3.45
1.2
1.4
—
—
—
0
0
9
18
5.20
3.41
1.0
1.3
—
—
—
0
0
35
188
2.06
3.35
2.4
1.7
—
—
—
0
0
6
7
8.81
3.28
1.0
1.1
94.50
87.99
iu/ml
—
6
7
20
85
2.52
3.28
1.4
1.7
—
—
—
0
0
10
24
4.34
3.24
1.2
1.4
—
—
—
0
0
7
11
6.56
3.21
1.0
1.1
—
—
—
0
0
64
426
1.77
3.21
1.5
1.2
1.10
2.01
u/ml
0.68
14
122
76
534
1.72
3.14
8.1
3.0
32.25
29.71
u/l
0.38
71
509
5
5
10.23
2.99
4.0
1.8
58.60
79.66
ug/l
—
5
5
11
32
3.59
2.95
1.8
1.7
—
—
—
0
0
10
27
3.85
2.92
1.0
1.4
—
—
—
0
0
32
179
1.95
2.74
3.3
4.7
2.78
71.25
ug/l
0.89
25
147
9
24
3.89
2.71
1.2
1.3
—
—
—
0
0
9
24
3.89
2.71
1.2
1.3
—
—
—
0
0
8
19
4.35
2.71
2.6
1.3
—
—
—
0
0
10
31
3.35
2.56
1.1
1.1
2.20
5.00
u/ml
—
5
13
10
31
3.35
2.56
1.2
1.5
—
—
—
0
0
7
16
4.50
2.50
1.0
1.1
—
—
—
0
0
7
16
4.50
2.50
1.0
1.3
—
—
—
0
0
9
27
3.45
2.42
3.2
1.3
—
—
—
0
0
11
42
2.72
2.18
1.8
1.3
—
—
—
0
0
5
10
5.10
2.08
1.0
1.1
—
—
—
0
0
134
1494
0.62
2.07
4.8
5.0
5.57
5.93
mmol/l
4.17
129
1370
7
21
3.42
1.98
1.6
3.5
31.66
89.41
u/ml
—
7
21
7
21
3.42
1.98
1.4
1.7
—
—
—
0
0
40
265
1.65
1.96
1.8
1.6
961.85
1267.90
nmol/l
1.70
34
200
5
11
4.64
1.95
1.8
1.2
—
—
—
0
0
64
475
1.53
1.95
5.1
3.2
0.00
0.00
estimate
-0.00
21
149
9
34
2.73
1.89
1.7
1.6
—
—
—
0
0
6
17
3.61
1.85
1.2
2.0
—
—
—
0
0
14
67
2.18
1.81
2.1
2.7
44.86
41.68
u/l
0.27
14
61
82
650
1.47
1.79
6.0
3.7
0.00
0.04
estimate
1.15
20
161
9
36
2.58
1.76
1.1
1.0
—
—
—
0
0
143
1557
0.63
1.70
5.6
5.9
2.84
2.73
mmol/l
0.86
137
1437
36
241
1.61
1.69
2.4
1.9
32.79
29.29
s
0.85
36
235
6
19
3.23
1.67
1.2
1.9
—
—
—
0
0
20
114
1.85
1.64
1.4
1.6
—
—
—
0
0
43
303
1.55
1.63
1.6
1.6
—
—
—
0
0
34
227
1.61
1.62
12.9
7.0
103.97
104.36
mmol/l
0.19
34
227
7
26
2.76
1.59
1.7
2.2
2.64
147.65
u/ml
—
7
26
55
412
1.48
1.57
4.2
2.8
324.75
337.55
umol/l
0.43
48
357
5
15
3.40
1.53
1.2
2.1
—
—
—
0
0
5
15
3.40
1.53
1.2
2.1
—
—
—
0
0
5
15
3.40
1.53
1.2
2.1
—
—
—
0
0
133
1460
0.68
1.49
4.4
4.3
1.28
1.27
mmol/l
0.07
128
1330
44
318
1.50
1.49
1.3
1.3
35.64
34.79
iu/ml
0.02
11
105
142
1538
0.66
1.45
5.2
5.1
4.76
4.69
mmol/l
0.36
136
1419
21
128
1.72
1.40
1.8
2.2
0.12
1.14
e6/l
0.76
21
122
20
122
1.72
1.34
3.0
3.3
52.07
82.18
ng/l
2.45
20
106
142
1531
0.68
1.30
5.2
5.0
1.49
1.52
mmol/l
0.39
135
1407
11
56
2.03
1.25
1.4
1.4
—
—
—
0
0
49
377
1.41
1.20
1.7
1.8
1.13
1.28
mg/l
0.21
38
300
10
50
2.06
1.19
2.2
1.8
—
—
—
0
0
8
39
2.10
1.17
1.1
1.2
—
26.13
—
0
7
12
65
1.91
1.16
1.2
1.5
—
—
—
0
0
20
128
1.63
1.14
2.3
1.4
—
—
—
0
0
39
291
1.43
1.12
1.3
1.3
10.52
18.27
u/ml
0.48
12
102
9
47
1.96
1.04
1.2
1.5
—
—
—
0
0
16
100
1.66
1.00
2.8
3.3
24.99
24.48
mmol/l
0.42
16
100
5
23
2.21
0.98
1.6
1.1
—
—
—
0
0
60
493
1.32
0.96
7.1
3.9
0.00
0.01
estimate
0.50
22
183
9
51
1.80
0.96
4.2
1.8
27.56
24.88
mmol/l
—
9
51
10
55
1.87
0.94
2.6
2.1
—
—
—
0
0
11
65
1.74
0.84
1.8
1.3
—
—
—
0
0
86
758
1.25
0.77
3.7
2.7
—
—
estimate
—
0
0
7
39
1.83
0.73
5.1
2.9
54.43
38.24
u/ml
—
7
39
47
389
1.28
0.71
6.5
3.8
1.02
1.02
kg/l
0.19
37
250
47
394
1.26
0.64
2.3
2.5
—
—
—
0
0
13
89
1.50
0.60
1.0
1.0
—
—
—
0
0
0
22
0.00
0.59
0.0
1.0
—
—
—
0
0
0
23
0.00
0.58
0.0
1.0
—
—
—
0
0
19
248
0.74
0.56
2.8
4.8
18.25
22.41
%
—
10
128
15
108
1.42
0.55
16.7
7.6
27.35
24.95
mmol/l
1.11
15
108
140
1466
0.81
0.53
6.6
6.3
39.66
39.14
mmol/mol
0.29
135
1367
161
1552
1.30
0.51
34.0
15.1
21.08
23.01
mg/l
0.34
147
1262
13
178
0.71
0.51
11.0
6.6
—
—
—
0
0
13
96
1.38
0.43
2.8
2.6
0.63
0.63
%
0.02
13
96
13
96
1.38
0.43
2.8
2.7
1.18
1.23
%
0.09
13
96
8
57
1.42
0.42
1.3
1.6
—
—
—
0
0
18
141
1.31
0.42
2.9
2.2
90.00
65.43
ml/min/173m2
—
7
61
5
33
1.53
0.41
3.0
2.4
6.00
92.58
ug/min
—
5
16
0
16
0.00
0.41
0.0
2.0
—
1.71
—
0
7
0
17
0.00
0.41
0.0
1.0
—
—
—
0
0
0
18
0.00
0.40
0.0
2.1
—
14.81
—
0
9
6
42
1.44
0.36
1.0
1.8
—
—
—
0
0
6
42
1.44
0.36
3.8
1.7
—
—
—
0
0
34
296
1.18
0.33
1.4
1.4
—
—
—
0
0
7
52
1.36
0.31
1.3
1.1
—
—
—
0
0
75
698
1.13
0.30
2.6
2.0
92.95
97.92
pmol/l
0.55
43
349
9
76
1.19
0.25
1.8
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
519.13
—
0
8
0
14
0.00
0.20
0.0
1.1
—
960.97
—
0
14
0
14
0.00
0.20
0.0
1.1
—
41.75
—
0
8
6
51
1.18
0.19
1.2
1.1
—
—
—
0
0
51
476
1.10
0.19
2.1
1.7
20.39
21.13
nmol/l
0.12
45
398
17
195
0.86
0.18
1.6
2.0
1.41
1.49
%
0.26
11
168
18
157
1.16
0.18
6.7
3.8
—
—
—
0
0
17
191
0.88
0.14
2.4
3.0
1.70
0.82
ug/l
0.37
11
125
64
619
1.05
0.09
3.8
3.7
99.91
34.02
ng/l
0.79
54
416
144
1458
0.94
0.08
6.8
5.6
1.73
1.92
mu/l
1.26
137
1347
11
98
1.13
0.08
1.8
1.9
—
—
—
0
0
97
987
0.96
0.06
3.3
3.2
—
—
—
0
0
16
172
0.92
0.06
2.2
1.9
—
—
—
0
0
20
190
1.06
0.04
2.1
2.1
—
—
—
0
0
13
121
1.08
0.04
1.4
1.2
45.39
126.24
u/ml
—
7
48
31
318
0.97
0.02
3.8
5.6
2.34
1.97
ug/l
0.20
25
284
124
1244
0.99
0.00
5.8
4.6
14.79
14.76
pmol/l
0.05
118
1138
69
694
0.99
0.00
2.0
1.9
1.29
1.36
mmol/l
0.37
60
582
51
513
0.99
0.00
3.5
4.0
4.20
8.93
mg/mmol
1.20
29
305
0
8
0.00
0.00
0.0
2.9
—
4.66
—
0
8
0
8
0.00
0.00
0.0
2.8
—
44.51
—
0
8
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
8
0.00
0.00
0.0
2.9
—
10.15
—
0
8
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
9
94
0.96
-0.00
1.3
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.3
—
51.57
—
0
7
0
7
0.00
-0.00
0.0
1.0
—
15.29
—
0
7
0
9
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.2
—
209.20
—
0
5
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_DERMATOMYOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_DERMATOMYOTH | 2.82 [2.11, 3.76] | < 0.001 |
| Birth year | 1.001 [0.99, 1.01] | 0.762 |
During the follow-up period (1.1.1998 — 31.12.2019), 120 out of 411 females with M13_DERMATOMYOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| M13_DERMATOMYOTH | 3.103 [2.28, 4.22] | < 0.001 |
| Birth year | 0.985 [0.98, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 69 out of 201 males with M13_DERMATOMYOTH died.
Mortality risk
Mortality risk for people of age
years, who have M13_DERMATOMYOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.228% | 0.515% |
| 5 | 1.755% | 3.094% |
| 10 | 4.592% | 7.916% |
| 15 | 9.262% | 14.67% |
| 20 | 16.456% | 24.478% |
Relationships between endpoints
↥Index endpoint: M13_DERMATOMYOTH – Other dermatomyositis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data